

## PATENT COOPERATION TREATY

**PCT**  
**NOTIFICATION OF ELECTION**  
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 25 April 2001 (25.04.01)	
<b>International application No.</b> PCT/EP00/08143	<b>Applicant's or agent's file reference</b> 99C111G1
<b>International filing date (day/month/year)</b> 09 August 2000 (09.08.00)	<b>Priority date (day/month/year)</b> 18 August 1999 (18.08.99)
<b>Applicant</b> COOKE, Tracey et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

21 February 2001 (21.02.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  Claudio Borton  Telephone No.: (41-22) 338.83.38
--	---

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/11965 A1**

(51) International Patent Classification<sup>7</sup>: A01N 43/40,  
47/12, 47/32, C07D 213/61, 409/12, 413/12, 417/12,  
213/65

[GB/FR]; 16, chemin Ferrand, F-69370 Saint Didier au  
Mont d'Or (FR).

(21) International Application Number: PCT/EP00/08143

(74) Agent: MERIGEAULT, Shona; Aventis CropScience  
S.A., 14-20, rue Pierre Baizet, B.P. 9163, F-69263 Lyon  
Cedex 09 (FR).

(22) International Filing Date: 9 August 2000 (09.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9919499.5 18 August 1999 (18.08.1999) GB  
9919500.0 18 August 1999 (18.08.1999) GB

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): AVEN-  
TIS CROPSCIENCE GMBH [DE/DE]; Brüningstrasse  
50, 65929 Frankfurt am Main (DE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): COOKE, Tracey  
[GB/GB]; 7 Larch Avenue, Brickett Wood, St Albans  
AL2 3SN (GB). HARDY, David [GB/GB]; 46 St. Bedes  
Gardens, Cambridge CB1 3UF (GB). MOLONEY, Brian  
[GB/GB]; 2 Crookdale Beck, Didcot, Oxon OX11 7US  
(GB). THOMAS, Peter, Stanley [GB/GB]; 94 Balsham  
Road, Linton, Cambridge CB1 6LW (GB). STEELE,  
Chris, Richard [GB/FR]; 46, boulevard de la Croix  
Rousse, F-69001 Lyon (FR). BRIGGS, Geoffrey, Gower

Published:

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: FUNGICIDES



(I)


(57) Abstract: The invention relates to compounds of general formula I, where A<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup> and Y are as defined in the description;  
and to their use as phytopathogenic fungicides.

WO 01/11965 A1

**Fungicides**

5 [0001] This invention relates to compounds having fungicidal activity.

[0002] In a first aspect the invention provides the use of a compound of general formula I, complexes and salts thereof as phytopathogenic fungicides




(I)

10 [0003] where

[0004]  $A^1$  is 2-pyridyl or its *N*-oxide, each of which may be substituted by up to four groups at least one of which is haloalkyl;

[0005] Y is a formula (D) or (E):



(E)

[0006]  $A^2$  is heterocyclyl or carbocyclyl, each of which may be substituted;

[0007]  $A^3$  is heterocyclyl or carbocyclyl, each of which may be substituted, or acyl;

[0008] L is a 3-atom linker, selected from the list:  $-N(R^5)C(=X)N(R^6)-$ ,

$-N(R^5)C(=X)CH(R^3)-$ ,  $-CH(R^3)N(R^5)CH(R^4)-$ ,  $-CH(R^3)N(R^5)C(=X)-$ ,

20  $-N(R^3)CH(R^4)C(=X)-$  and  $-O-N(R^5)C(=X)-$ ; wherein  $A^1$  is attached to the left hand side of linker L;

[0009]  $L^1$  is a 4-atom linker selected from the list:  $-N(R^9)C(=X)-X^1-CH(R^7)-$ ,

$-N(R^9)C(=X)CH(R^7)CH(R^8)-$ ,  $-N(R^9)C(=X)C(R^7)=C(R^8)-$ ,

$-N(R^9)C(R^7)=C(R^8)-C(=X)-$ ,  $-N(R^9)C(R^7)=C(R^8)-SO_2-$ ,

25  $-N(R^9)C(=X)C(R^7)(R^8)-SO_2-$  and  $-N(R^9)C(=X)C(R^7)(R^8)-X^1-$ ; wherein  $A^1$  is attached to the left hand side of linker  $L^1$ ;

[0010]  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^7$  and  $R^8$ , which may be the same or different, are  $R^b$ , cyano, nitro, halogen,  $-OR^b$ ,  $-SR^b$  or optionally substituted amino;

[0011]  $R^5$  and  $R^6$  which may be the same or different, are  $R^b$ , cyano or nitro; or any  $R^1$ ,  $R^3$  or  $R^5$  group, together with the interconnecting atoms, can form a 3-, 4-, 5- or 6-membered ring with any  $R^2$ ,  $R^4$  or  $R^6$  or any  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  or  $R^6$  group, together with the interconnecting atoms can form a 5- or 6-membered ring with  $A^2$ ;

[0012] or  $R^1$  and  $R^2$ , or  $R^7$  and  $R^8$ , together with the interconnecting atoms, may form a 3-, 4-, 5- or 6-membered ring, which may be substituted;

[0013]  $R^b$  is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen or acyl;

[0014] X is oxygen or sulfur;

[0015]  $X^1$  is oxygen, sulfur or  $-N(R^9)-$ ; and

[0016]  $R^9$  is  $R^b$ , cyano or nitro, or  $R^9$  and  $A^3$ ,  $R^1$ ,  $R^2$ ,  $R^7$  or  $R^8$ , together with the interconnecting atoms, may form a 3-, 4-, 5- or 6-membered ring, which may be substituted.

[0017] Preferred substituents on the 2-pyridyl group ( $A^1$ ) are halogen, hydroxy, cyano, nitro,  $SF_5$ , trialkylsilyl, optionally substituted amino, acyl, or a group  $-R^a$ ,  $-OR^a$  or  $-SR^a$ , or a group  $-C(R^a)=N-Q$ , where Q is  $-R^a$ ,  $-OR^a$ ,  $-SR^a$  or optionally substituted amino, wherein  $R^a$  is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; or two adjacent substituents together with the atoms to which they are attached form an optionally substituted ring which can contain up to 3 hetero atoms.

Preferably, the 2-pyridyl group is substituted at the 3 and/or 5 position.

[0018] Preferred compounds are those in which one or more of the following features are present:

[0019] A<sup>2</sup> is optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted cyclohexyl or optionally substituted cyclopropyl; or

[0020] A<sup>3</sup> is optionally substituted phenyl, optionally substituted heterocyclyl or acyl; or

5 [0021] R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>7</sup> and R<sup>8</sup> are hydrogen, optionally substituted alkyl, optionally substituted phenyl, cyano, acyl or halogen (more preferably R<sup>1</sup> and R<sup>2</sup> are hydrogen); or

R<sup>5</sup> and R<sup>6</sup> are hydrogen, optionally substituted alkyl or acyl; or

R<sup>7</sup> and R<sup>8</sup> are hydrogen, optionally substituted alkyl or acyl; or

10 R<sup>9</sup> is hydrogen or optionally substituted alkyl; or

the 2-pyridyl group (A<sup>1</sup>) is substituted by alkoxy, alkyl, cyano, halogen, nitro, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl or trifluoromethyl, (preferably chlorine or trifluoromethyl).

15 [0022] Many of the compounds of formula I are novel. Therefore, according to a further aspect, the invention provides compounds of formula I where:

Y is -L-A<sup>2</sup>- and:

L is -NHC(=X)NH-; and

A<sup>2</sup> is phenyl optionally substituted by halogen, haloalkyl, phenoxy, alkoxy, alkyl,

20 CN, NO<sub>2</sub>, SO<sub>2</sub>-(N-tetrahydropyridinyl), alkylthio, acyl, phenylsulphonyl, dialkylamino, alkylsulphonyl, benzylsulphonyl, S(phenyl substituted by halogen); or

A<sup>2</sup> is cycloalkyl; or naphthyl optionally substituted by NO<sub>2</sub>; or

L is -NHC(=O)CH(R<sup>3</sup>)-;

R<sup>3</sup> is hydrogen, alkyl, phenyl, halogen or acyloxy;

25 A<sup>2</sup> is phenyl optionally substituted by halogen, NO<sub>2</sub> or alkoxy; or thienyl; or imidazolyl; or pyrrolinyl substituted by alkoxy; or

L is -CH(R<sup>3</sup>)N(R<sup>5</sup>)CH<sub>2</sub>-;

R<sup>3</sup> is N-alkylcarbamoyl or alkoxycarbonyl;

R<sup>5</sup> is hydrogen or acyl;

A<sup>2</sup> is phenyl optionally substituted by alkyl, alkoxy, halogen, NO<sub>2</sub>, haloalkyl or phenoxy; or is naphthyl; or

L is -CH(R<sup>3</sup>)NHC(=O)-;

5 R<sup>3</sup> is N-alkylcarbamoyl or alkoxycarbonyl;

A<sup>2</sup> is phenyl optionally substituted by alkoxy, halogen, NO<sub>2</sub>, haloalkyl, phenoxy or phenyl; or is cycloalkyl; or

L is -O-NHC(=O)- and A<sup>2</sup> is phenyl substituted by alkyl;

or

10 Y is -L<sup>1</sup>-A<sup>3</sup>- and:

L<sup>1</sup> is -NHC(=O)(CH<sub>2</sub>)<sub>2</sub>-, and A<sup>3</sup> is phenyl substituted by alkyl; or

L<sup>1</sup> is -NHC(=S)NHCH<sub>2</sub>-, and A<sup>3</sup> is phenyl; or

L<sup>1</sup> is -NHC(=O)CH(alkyl)S-, and A<sup>3</sup> is phenyl; or

L<sup>1</sup> is -NHC(=O)OCH<sub>2</sub>-, -NHC(=O)(CH<sub>2</sub>)<sub>2</sub>-, -NHC(=O)NHCH<sub>2</sub>-,

15 -NHC(=S)NHCH<sub>2</sub>-, -N(alkyl)C(=O)CH<sub>2</sub>O- or -NHC(=O)CH<sub>2</sub>O-;

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is hydrogen or alkoxycarbonyl;

A<sup>3</sup> is phenyl optionally substituted by halogen, alkyl, phenyl, OH, alkoxy or alkoxycarbonyl; or fluorenyl; or pyridyl optionally substituted by halogen or

20 haloalkyl; or thiadiazolyl substituted by alkyl; or benzthiazolyl optionally substituted by halogen or by phenyl substituted by halogen; or quinolinyl substituted by haloalkyl; or triazolyl substituted by alkyl or phenyl; or tetrazolyl substituted by alkyl or cycloalkyl; or pyrimidinyl substituted by alkyl; or benzoxazolyl; or imidazolyl substituted by alkyl; or thiazolinyl substituted by alkyl and methylene; or

25 L<sup>1</sup> is -NHC(=O)CH(R<sup>8</sup>)N(R<sup>9</sup>)-;

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is hydrogen or alkyl;

R<sup>8</sup> and R<sup>9</sup> are each hydrogen or alkyl;

A<sup>3</sup> is benzoyl optionally substituted by alkyl; or benzyloxycarbonyl; or alkoxycarbonyl; or

L<sup>1</sup> is -NHC(=O)CH(alkyl)SO<sub>2</sub>-;

R<sup>1</sup> and R<sup>2</sup> are each hydrogen;

5 A<sup>3</sup> is phenyl; or

L<sup>1</sup> is -NHC(=O)CH<sub>2</sub>X<sup>1</sup>-; where X<sup>1</sup> and A<sup>3</sup> form a 2-oxo-N-benzthiazolyl ring which is substituted by halogen; and

R<sup>1</sup> and R<sup>2</sup> are each hydrogen.

10 **[0023]** The invention also includes any of the compounds specifically exemplified hereinafter.

**[0024]** Any alkyl group may be straight or branched and is preferably of 1 to 10 carbon atoms, especially 1 to 7 and particularly 1 to 5 carbon atoms.

15

**[0025]** Any alkenyl or alkynyl group may be straight or branched and is preferably of 2 to 7 carbon atoms and may contain up to 3 double or triple bonds which may be conjugated, for example vinyl, allyl, butadienyl or propargyl.

20 **[0026]** Any carbocyclyl group may be saturated, unsaturated or aromatic, and contain 3 to 8 ring-atoms. Preferred saturated carbocyclyl groups are cyclopropyl, cyclopentyl or cyclohexyl. Preferred unsaturated carbocyclyl groups contain up to 3 double bonds. A preferred aromatic carbocyclyl group is phenyl. The term carbocyclic should be similarly construed. In addition, the term carbocyclyl includes any fused  
25 combination of carbocyclyl groups, for example naphthyl, phenanthryl, indanyl and indenyl.

**[0027]** Any heterocyclyl group may be saturated, unsaturated or aromatic, and contain 5 to 7 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen.  
30 oxygen and sulfur. Examples of heterocyclyl groups are furyl, thienyl, pyrrolyl.

pyrrolinyl, pyrrolidinyl, imidazolyl, dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, pyridazinyl, pyrimidinyl, 5 pyrazinyl, piperazinyl, sulfolanyl, tetrazolyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl, diazepinyl and thiazolinyl. In addition, the term heterocyclyl includes fused heterocyclyl groups, for example benzimidazolyl, benzoxazolyl, imidazopyridinyl, benzoxazinyl, benzothiazinyl, oxazolopyridinyl, benzofuranyl, quinolinyl, quinazolinyl, quinoxalinyl, dihydroquinazolinyl, benzothiazolyl, 10 phthalimido, benzofuranyl, benzodiazepinyl, indolyl and isoindolyl. The term heterocyclic should be similarly construed.

[0028] Any alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl group, when substituted, may be substituted by one or more substituents, which may be the same or different, and may be selected from the list: hydroxy; mercapto; azido; nitro; 15 halogen; cyano; acyl; optionally substituted amino; optionally substituted carbocyclyl; optionally substituted heterocyclyl; cyanato; thiocyanato; -SF<sub>5</sub>; -OR<sup>a</sup>; -SR<sup>a</sup> and -Si(R<sup>a</sup>)<sub>3</sub>, where R<sup>a</sup> is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted. In the case of any carbocyclyl or heterocyclyl group the list includes additionally: alkyl, alkenyl and alkynyl, each of which may be 20 substituted. Preferred substituents on any alkyl, alkenyl or alkynyl group are alkoxy, haloalkoxy or alkylthio, each containing 1 to 5 carbon atoms; halogen; or optionally substituted phenyl. Preferred substituents on any carbocyclyl or heterocyclyl group are alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio, each containing 1 to 5 carbon 25 atoms; halogen; or optionally substituted phenyl.

[0029] In the case of any alkyl group or any unsaturated ring-carbon in any carbocyclyl or heterocyclyl group the list includes a divalent group such as oxo or imino, which may be substituted by optionally substituted amino, R<sup>a</sup> or -OR<sup>a</sup>. 30 Preferred groups are oxo, imino, alkylimino, oximino, alkyloximino or hydrazono.



[0030] Any amino group, when substituted and where appropriate, may be substituted by one or two substituents which may be the same or different, selected from the list: optionally substituted alkyl, optionally substituted amino, -OR<sup>a</sup> and acyl groups. Alternatively two substituents together with the nitrogen to which they are attached may form a heterocyclyl group, preferably a 5 to 7-membered heterocyclyl group, which may be substituted and may contain other hetero atoms, for example morpholino, thiomorpholino or piperidinyl.

[0031] The term acyl includes the residues of sulfur and phosphorus-containing acids as well as carboxylic acids. Typically the residues are covered by the general formulae -C(=X<sup>a</sup>)R<sup>c</sup>, -S(O)<sub>p</sub>R<sup>c</sup> and -P(=X<sup>a</sup>)(OR<sup>a</sup>)(OR<sup>a</sup>), where appropriate X<sup>a</sup> is O or S, R<sup>c</sup> is as defined for R<sup>a</sup>, -OR<sup>a</sup>, -SR<sup>a</sup>, optionally substituted amino or acyl; and p is 1 or 2. Preferred groups are -C(=O)R<sup>d</sup>, -C(=S)R<sup>d</sup>, and -S(O)<sub>p</sub>R<sup>d</sup> where R<sup>d</sup> is alkyl, C<sub>1</sub> to C<sub>5</sub> alkoxy, C<sub>1</sub> to C<sub>5</sub> alkylthio, phenyl, heterocyclyl or amino, each of which may be substituted.

[0032] By the term "salts" is meant salts the cations or anions of which are known and accepted in the art for the formation of salts for agricultural or horticultural use. Suitable salts with bases include alkali metal (e.g. sodium and potassium), alkaline earth metal (e.g. calcium and magnesium), ammonium and amine (e.g. diethanolamine, triethanolamine, octylamine, morpholine and dioctylmethylamine) salts. Suitable acid addition salts, e.g. formed by compounds of formula I containing an amino group, include salts with inorganic acids, for example hydrochlorides, sulphates, phosphates and nitrates and salts with organic acids for example acetic acid.

[0033] Complexes of compounds of the invention are usually formed from a salt of formula MAn<sub>2</sub>, in which M is a divalent metal cation, e.g. copper, manganese, cobalt, nickel, iron or zinc and An is an anion, e.g. chloride, nitrate or sulfate.

[0034] In cases where the compounds of the invention exist as the E and Z isomers, the invention includes individual isomers as well as mixtures thereof.

5 [0035] In cases where compounds of the invention exist as tautomeric isomers, the invention includes individual tautomers as well as mixtures thereof.

[0036] In cases where the compounds of the invention exist as optical isomers (for example where  $R^1$  and  $R^2$  are different), the invention includes individual isomers as  
10 well as mixtures thereof.

[0037] The compounds of the invention have activity as fungicides, especially against fungal diseases of plants, e.g. mildews and particularly cereal powdery mildew (*Erysiphe graminis*) and vine downy mildew (*Plasmopara viticola*), rice  
15 blast (*Pyricularia oryzae*), cereal eyespot (*Pseudocercospora herpotrichoides*), rice sheath blight (*Pellicularia sasakii*), grey mould (*Botrytis cinerea*), damping off (*Rhizoctonia solani*), wheat brown rust (*Puccinia recondita*), late tomato or potato blight (*Phytophthora infestans*), apple scab (*Venturia inaequalis*), and glume blotch (*Leptosphaeria nodorum*). Other fungi against which the compounds may be active  
20 include other powdery mildews, other rusts, and other general pathogens of Deuteromycete, Ascomycete, Phycomycete and Basidiomycete origin.

[0038] The invention thus also provides a method of combating fungal pests such as phytopathogenic fungi at a locus infested or liable to be infested therewith, which  
25 comprises applying to the locus a compound of formula I or a complex or salt thereof.

[0039] The invention also provides an agricultural composition comprising a compound of formula I or a complex or salt thereof in admixture with an  
30 agriculturally acceptable diluent or carrier.

[0040] The composition of the invention may of course include more than one compound of the invention.

[0041] In addition, the composition can comprise one or more additional active ingredients, for example compounds known to possess plant-growth regulant, herbicidal, fungicidal, insecticidal, acaricidal, antimicrobial or antibacterial properties. Alternatively the compound of the invention can be used in sequence with the other active ingredient.

[0042] The diluent or carrier in the composition of the invention can be a solid or a liquid optionally in association with a surface-active agent. for example a dispersing agent, emulsifying agent or wetting agent. Suitable surface-active agents include anionic compounds such as a carboxylate, for example a metal carboxylate of a long chain fatty acid; an *N*-acylsarcosinate; mono- or di-esters of phosphoric acid with fatty alcohol ethoxylates or alkyl phenol ethoxylates or salts of such esters; fatty alcohol sulfates such as sodium dodecyl sulfate, sodium octadecyl sulfate or sodium cetyl sulfate; ethoxylated fatty alcohol sulfates; ethoxylated alkylphenol sulfates; lignin sulfonates; petroleum sulfonates; alkyl-aryl sulfonates such as alkyl-benzene sulfonates or lower alkylnaphthalene sulfonates, e.g. butyl-naphthalene sulfonate; salts of sulfonated naphthalene-formaldehyde condensates; salts of sulfonated phenol-formaldehyde condensates; or more complex sulfonates such as the amide sulfonates, e.g. the sulfonated condensation product of oleic acid and *N*-methyl taurine; the dialkyl sulfosuccinates, e.g. the sodium sulfonate of dioctyl succinate; acid derivatives of alkyl glycosides and alkylpolyglycosides materials and their metal salts, e.g. alkyl polyglycoside citrate or tartrate materials; or mono-, di- and tri-alkyl esters of citric acid and their metal salts.

[0043] Nonionic agents include condensation products of fatty acid esters, fatty alcohols, fatty acid amides or fatty-alkyl- or alkenyl-substituted phenols with ethylene and/or propylene oxide; fatty esters of polyhydric alcohol ethers, e.g. sorbitan fatty acid esters; condensation products of such esters with ethylene oxide,

e.g. polyoxyethylene sorbitan fatty acid esters; alkyl glycosides, alkyl polyglycoside materials; block copolymers of ethylene oxide and propylene oxide; acetylenic glycols such as 2,4,7,9-tetramethyl-5-decyne-4,7-diol, ethoxylated acetylenic glycols; acrylic based graft copolymers; alkoxylated siloxane surfactants; or imidazoline type surfactants, e.g. 1-hydroxyethyl-2-alkylimidazoline.

[0044] Examples of a cationic surface-active agent include, for instance, an aliphatic mono-, di-, or polyamine as an acetate, naphthenate or oleate; an oxygen-containing amine such as an amine oxide, polyoxyethylene alkylamine or polyoxypropylene alkylamine; an amide-linked amine prepared by the condensation of a carboxylic acid with a di- or polyamine; or a quaternary ammonium salt.

[0045] The compositions of the invention can take any form known in the art for the formulation of agrochemicals, for example, a solution, an aerosol, a dispersion, an aqueous emulsion, a microemulsion, a dispersible concentrate, a dusting powder, a seed dressing, a fumigant, a smoke, a dispersible powder, an emulsifiable concentrate, granules or an impregnated strip. Moreover it can be in a suitable form for direct application or as a concentrate or primary composition which requires dilution with a suitable quantity of water or other diluent before application.

[0046] A dispersible concentrate comprises a compound of the invention dissolved in one or more water miscible or semi-water miscible solvents together with one or more surface active and/or polymeric material. Addition of the formulation to water results in the crystallisation of the active ingredient, the process being controlled by the surfactants and/or polymers resulting in a fine dispersion.

[0047] A dusting powder comprises a compound of the invention intimately mixed and ground with a solid pulverulent diluent, for example, kaolin.

[0048] An emulsifiable concentrate comprises a compound of the invention dissolved in a water-immiscible solvent which forms an emulsion or microemulsion on addition to water in the presence of an emulsifying agent.

5 [0049] A granular solid comprises a compound of the invention associated with similar diluents to those that may be employed in dusting powders, but the mixture is granulated by known methods. Alternatively it comprises the active ingredient absorbed or coated on a pre-formed granular carrier, for example, Fuller's earth, attapulgite, silica or limestone grit.

10

[0050] Wettable powders, granules or grains usually comprise the active ingredient in admixture with suitable surfactants and an inert powder diluent such as clay or diatomaceous earth.

15 [0051] Another suitable concentrate is a flowable suspension concentrate which is formed by grinding the compound with water or other liquid, surfactants and a suspending agent.

[0052] The concentration of the active ingredient in the composition of the present invention, as applied to plants is preferably within the range of 0.0001 to 1.0 per cent by weight, especially 0.0001 to 0.01 per cent by weight. In a primary composition, the amount of active ingredient can vary widely and can be, for example, from 5 to 20 95 per cent by weight of the composition.

25 [0053] The invention is generally applied to seeds, plants or their habitat. Thus, the compound can be applied directly to the soil before, at or after drilling so that the presence of active compound in the soil can control the growth of fungi which may attack seeds. When the soil is treated directly the active compound can be applied in any manner which allows it to be intimately mixed with the soil such as by spraying, 30 by broadcasting a solid form of granules, or by applying the active ingredient at the same time as drilling by inserting it in the same drill as the seeds. A suitable

application rate is within the range of from 5 to 1000 g per hectare, more preferably from 10 to 500 g per hectare.

[0054] Alternatively the active compound can be applied directly to the plant by, for example, spraying or dusting either at the time when the fungus has begun to appear on the plant or before the appearance of fungus as a protective measure. In both such cases the preferred mode of application is by foliar spraying. It is generally important to obtain good control of fungi in the early stages of plant growth, as this is the time when the plant can be most severely damaged. The spray or dust can conveniently contain a pre- or post-emergence herbicide if this is thought necessary. Sometimes, it is practicable to treat the roots, bulbs, tubers or other vegetative propagule of a plant before or during planting, for example, by dipping the roots in a suitable liquid or solid composition. When the active compound is applied directly to the plant a suitable rate of application is from 0.025 to 5 kg per hectare, preferably from 0.05 to 1 kg per hectare.

[0055] In addition, the compounds of the invention can be applied to harvested fruits, vegetables or seeds to prevent infection during storage.


[0056] In addition, the compounds of the invention can be applied to plants or parts thereof which have been genetically modified to exhibit a trait such as fungal and/or herbicidal resistance.

[0057] In addition the compounds of the invention can be used to treat fungal infestations in timber and in public health applications.

[0058] Compounds of the invention may be prepared, in known manner, in a variety of ways. Such processes for the preparation of novel compounds of formula I constitute a feature of the invention.


[0059] Compounds of formula Ia, i.e. compounds of general formula I where Y is a formula (D) and L is  $-N(R^5)C(=X)NH-$ , can be prepared by reacting compounds of formula II or their hydrochloride salts, with compounds of formula III according to reaction scheme 1. A preferred base is triethylamine.

5

Scheme 1

[0060] Compounds of formula Ib, i.e. compounds of general formula I where Y is of formula (D) and L is  $-N(R^5)C(=O)CH(R^3)-$ , may be prepared by reacting compounds of formula IV with compounds of formula II according to reaction scheme 2. A variety of methods are available to the chemist, for example, generation of the acid chloride of IV, using reagents such as phosphoryl chloride or oxalyl chloride, followed by addition of II. Alternatively, carbonyl diimidazole (CDI) can be used to activate compounds of formula IV prior to addition of II.

15


Scheme 2

[0061] Compounds of formula Ic and Id, i.e. compounds of general formula I where Y is of formula (D) and L is  $-CH(R^3)-N(R^5)-W-$  and W is  $-C(=X)-$  or  $-CH(R^4)-$ ,

20


wherein  $R^3$  is alkoxycarbonyl or carbamoyl respectively, can be prepared by various methods known to the skilled chemist. In particular, compounds of formula Ic or Id may be prepared from solid supported reagents of formula V according to reaction scheme 3, wherein the black circle represents Merrifield resin.

5

Scheme 3

[0062] Compounds of formula Ie, i.e. compounds of general formula I where Y is of formula (D) and L is  $-\text{CH}(\text{R}^3)\text{N}(\text{R}^5)\text{C}(=\text{X})-$  may be prepared by reacting compounds of formula VI with compounds of formula VII according to reaction scheme 4.


10

Scheme 4




[0063] Compounds of formula If, i.e. compounds of general formula I where Y is of formula (B) and  $L^1$  is  $-N(R^9)C(=X)-L^2-$ , where  $L^2$  is  $-\text{CH}(R^7)\text{CH}(R^8)-$ ,  $-\text{C}(R^8)(R^7)-X^1-$  or  $-\text{C}(R^7)=\text{C}(R^8)-$ , may be prepared according to Scheme 5 by reacting compounds of formula VIII or their hydrochloride salts with compounds of formula IX in the presence of a base, where  $Q^1$  is a leaving group such as halogen, preferably chlorine. A preferred base is triethylamine. Compounds of formula IX can either be isolated or generated *in situ*.

Scheme 5



[0064] Compounds of formula Ig, i.e. compounds of general formula I where Y is of formula (E) and  $L^1$  is  $-N(R^9)C(=X)-NH-\text{CH}(R^7)-$ , may be prepared according to Scheme 6 by reacting compounds of formula VIII or their hydrochloride salts with compounds of formula X. A preferred base is triethylamine.

Scheme 6




20 [0065] Compounds of formula Ih, i.e. compounds of general formula I where Y is of formula (E) and  $L^1$  is  $-N(R^9)C(=X)-\text{C}(R^7)(R^8)-X^1-$  wherein  $R^7$  and  $R^8$  are not both

hydrogen and X is oxygen, may also be prepared according to Scheme 7 by reacting compounds of formula XI where  $Q^1$  is a leaving group, preferably bromine, with  $A^2-X^1-H$  in the presence of a suitable base, preferably potassium *tert*-butoxide.

5


Scheme 7



[0066] Compounds of formula Ii, i.e. compounds of general formula I where Y is of formula (E) and  $L^1$  is  $-N(R^9)C(R^7)=C(R^8)-C(=X)-$  wherein  $R^7$  is not hydrogen, may be prepared according to Scheme 8 by reacting compounds of formula VIII or their hydrochloride salts in the presence of a suitable base such as sodium acetate with compounds of formula XII.

10

Scheme 8




15

[0067] Compounds of formula Ij, i.e. compounds of general formula I where Y is of formula (E) and  $L^1$  is  $-N(R^9)CH=C(R^8)-C(=X)-$ , may be prepared according to Scheme 9 by reacting compounds of formula VIII or their hydrochloride salts in the presence of a suitable base such as sodium acetate with compounds of formula XIII.


20

Scheme 9



[0068] Compounds of formula Ik, i.e. compounds of general formula I where Y is of formula (E) and L<sup>1</sup> is -N(R<sup>9</sup>)C(=X)O-C(H)(R<sup>7</sup>)-, may be prepared according to Scheme 10 by reacting compounds of formula VIII or their hydrochloride salts in the presence of a suitable base such as triethylamine with compounds of formula XIV.

Scheme 10



[0069] Collections of compounds of formula (I) may also be prepared in a parallel manner, either manually, automatically or semi-automatically. This parallel preparation may be applied to the reaction procedure, work-up or purification of products or intermediates. For a review of such procedures see by S.H. DeWitt in "Annual Reports in Combinatorial Chemistry and Molecular Diversity: Automated synthesis", Volume 1, Verlag Escom 1997, pages 69 to 77.


[0070] Furthermore, compounds of the formula (I) may be prepared using solid-supported methods, where the reactants are bound to a synthetic resin. See for example: Barry A. Bunin in "The Combinatorial Index", Academic Press, 1998 and

"The tea-bag method" (Houghten, US 4,631,211; Houghten et al., Proc. Natl. Acad. Sci, 1985, 82, 5131-5135).

[0071] The preparation of the processes described herein yields compounds of the formula (I) in the form of substance collections which are termed libraries. The present invention also relates to libraries which comprise at least two compounds of the formula (I).


[0072] Intermediates of formula V may be prepared in turn from compounds of formula XV, by methods analogous to that depicted in reaction scheme 11. Compounds of formula Va may be prepared by treating XV with a compound of formula XVI in the presence of a suitable base, such as triethylamine. Compounds of formula Vb may be prepared from compounds of formula XVa by treatment with compounds of formula XVII, sodium cyanoborohydride and acetic acid followed by reaction with compounds of formula XVIII and triethylamine.

Scheme 11



[0073] Compounds of formula XV can be prepared using similar methods to reaction scheme 12.

Scheme 12




5

[0074] Intermediates of formula VIII may be prepared by methods described in international application PCT/GB/99/00304.

[0075] Intermediates of formula IX can be prepared from the corresponding carboxylic acid by methods known to the skilled chemist.

10 [0076] Intermediates of formula XI may be prepared according to Scheme 13 by reacting compounds of formula VIII in the presence of a suitable base such as triethylamine with compounds of formula XIX, in the presence of a carbonyl diimidazole (CDI).

Scheme 13



[0077] Other methods will be apparent to the chemist skilled in the art, as will be the methods for preparing starting materials and intermediates.


[0078] The invention is illustrated in the following Examples. Structures of isolated, novel compounds were confirmed by <sup>1</sup>H NMR (in CDCl<sub>3</sub>) and/or other appropriate analyses.

#### [0079] Example 1

##### N-(2-Chlorophenyl)-N'-[(3-chloro-5-trifluoromethyl-2-pyridyl)methyl]thiourea (Compound 30)

To a suspension of (3-chloro-5-trifluoromethyl-2-pyridyl)methylamine hydrochloride (0.12 g) and 2-chlorophenylisothiocyanate (0.09 g) in dry tetrahydrofuran (10 ml) was added 10 drops of triethylamine. The mixture was stirred at room temperature overnight. The solvent was removed by evaporation *in vacuo* and the residue extracted with ethyl acetate and washed with 2M hydrochloric acid. The layers were separated and the organic phase was evaporated to dryness to give the title product. m.p. 126°C.


[0080] The following compounds of formula Im (see Table A), i.e. compounds of general formula I where Y is of formula (D) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl, R<sup>1</sup> and R<sup>2</sup> are hydrogen and L is -NHC(=X)NH-, may be prepared by methods analogous to those of Example 1.



(Im)

**Table A**

Cmp	X	A <sup>2</sup>	Characterising data
1	O	phenyl	m.p. 143-6 °C
2	S	phenyl	m.p. 151 °C
3	O	cyclohexyl	m.p. 135 °C
4	O	2-Cl-phenyl	m.p. 125 °C
5	O	2,3-diCl-phenyl	m.p. 142 °C
6	O	3,5-diCl-phenyl	m.p. 81 °C
7	O	4-Cl-phenyl	m.p. 180 °C
8	O	2-CF <sub>3</sub> -phenyl	m.p. 161 °C
9	O	4-PhO-phenyl	m.p. 162 °C
10	O	2,4-diCl-phenyl	m.p. 90 °C
11	O	3,4-diMeO-phenyl	m.p. 179 °C
12	O	2,6-xylyl	m.p. 175-7 °C
13	O	2,6-diCl-phenyl	m.p. 178 °C
14	O	3-tolyl	m.p. 165-7 °C
15	O	3,4-diCl-phenyl	m.p. 132 °C
16	O	3-CF <sub>3</sub> -phenyl	<sup>1</sup> H N.M.R δ (ppm) 4.7 (2H. d), 6.7 (1H. s), 7.2 (1H. d), 7.3 (1H. t), 7.5 (1H. d), 7.6 (1H. s), 7.85 (1H. s), 8.1 (1H. s), 8.5 (1H. s).
17	O	3-MeO-phenyl	m.p. 118 °C
18	O	4-CF <sub>3</sub> -phenyl	m.p. 167-8 °C
19	O	4-CN-phenyl	m.p. 209-13 °C
20	O	2-MeO-phenyl	m.p. 144-6 °C
21	O	4-MeO-phenyl	m.p. 192 °C
22	O	2,4-diMeO-phenyl	m.p. 172 °C

Cmp	X	A <sup>2</sup>	Characterising data
23	O	3-NO <sub>2</sub> -phenyl	m.p. 94 °C
24	O	2-NO <sub>2</sub> -phenyl	m.p. 137-9 °C
25	O	4-tolyl	m.p. 201 °C
26	O	2-tolyl	m.p. 138 °C
27	O	3-Br-phenyl	m.p. 104 °C
28	O	4-Br-phenyl	m.p. 181-5 °C
29	S	cyclopropyl	m.p. 102 °C
30	S	2-Cl-phenyl	m.p. 126 °C
31	S	4-Cl-phenyl	m.p. 153 °C
32	S	3,5-diCl-phenyl	m.p. 179 °C
33	S	2,4-diCl-phenyl	m.p. 160 °C
34	S	2,3-diCl-phenyl	m.p. 170-2 °C
35	S	2-CF <sub>3</sub> -phenyl	m.p. 140-2 °C
36	S	2,6-xylyl	m.p. 170-3 °C
37	S	3,4-diMeO-phenyl	m.p. 172-5 °C
38	S	3-PhO-phenyl	m.p. 152-3 °C
39	S		oil
40	S	3-MeS-phenyl	m.p. 142-3 °C
41	S	3-acetylphenyl	m.p. 160 °C
42	S	3-Cl-4-tolyl	m.p. 163 °C
43	S	3-(PhSO <sub>2</sub> )-phenyl	m.p. 195-8 °C
44	S	4-But-phenyl	m.p. 108-9 °C
45	S	3-CF <sub>3</sub> -phenyl	m.p. 158-60 °C
46	S	4-NMe <sub>2</sub> -phenyl	m.p. 177-81 °C
47	S	4-MeSO <sub>2</sub> -phenyl	m.p. 160-3 °C
48	S	4-MeS-phenyl	m.p. 172-6 °C
49	S	6-NO <sub>2</sub> -2-naphthyl	m.p. 194-8 °C




Cmp	X	A <sup>2</sup>	Characterising data
50	S	2-tolyl	m.p. 158-60 °C
51	S	2-Pr <sup>i</sup> -phenyl	m.p. 124-7°C
52	S	2,6-diCl-phenyl	m.p. 186-9 °C
53	S	4-Br-phenyl	m.p. 143-5 °C
54	S	2-Cl-4-MeSO <sub>2</sub> -phenyl	m.p. 176-8 °C
55	S	4-Me-2-NO <sub>2</sub> -phenyl	m.p. 136-9 °C
56	S	2-Cl-4-PrSO <sub>2</sub> -phenyl	m.p. 166-9 °C
57	S	4-(4-Me-benzylsulfonyl)phenyl	m.p. 185-9 °C
58	S	4-(4-Cl-phenylthio)phenyl	m.p. 147-50 °C
59	S	cyclohexyl	<sup>1</sup> H N.M.R δ (ppm) 1.1-2.1 (10H, m), 3.8 (1H, br), 5.0 (2H, br), 6.5 (1H, br), 7.4 (1H, br), 8.0 (1H, s) and 8.7 (1H, s)
60	S	4-PhO-phenyl	m.p. 109-10°C
61	S	2-PhO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.63 (1H, s), 8.1 (2H, d), 7.95 (1H, s), 7.65 (1H, s), 7.65 (1H, d), 7.4-6.9 (8H, m) and 5.1 (2H, d).
62	S	3-Pr <sup>i</sup> O-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.6 (1H, s), 8.18 (1H, s), 8.04 (1H, br), 7.95 (1H, s), 7.35 (1H, t), 6.86 (3H, d), 5.1 (2H, d), 4.58 (1H, m), 1.35 (6H, d)
63	S	3,4-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.6 (1H, s), 8.0 (1H, s), 7.5-7.1 (3H, m), 4.9 (2H, d), 4.7 (2H, d)
64	S	2-MeO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H, s), 8.05 (1H, br), 7.9 (1H, s), 7.85 (1H, br), 7.5 (1H, d), 7.25 (1H, dd), 7.0 (2H, dd), 5.1 (2H, d), 3.85 (3H, s)

**[0081] Example 2**N-[(3-Chloro-5-trifluoromethyl-2-pyridyl)methyl]-2-nitrophenylacetamide(Compound 108)

- 5 To a stirred suspension of 2-nitrophenylacetic acid (0.36 g) in dry toluene (5 ml) at room temperature was added phosphoryl chloride (0.37 g) and stirring was continued overnight. Meanwhile a solution of the amine was prepared. (3-Chloro-5-

trifluoromethyl-2-pyridyl)methylamine hydrochloride (0.49 g) in dry toluene (5 ml) and triethylamine (1.23 g) was stirred at room temperature for 1 hour and then filtered. The solid was washed with dry toluene and the combined filtrates were added dropwise to the above suspension of acid chloride with ice-cooling. After  
 5 addition, the mixture was stirred at room temperature overnight. Dichloromethane was added and the mixture was washed with water. The aqueous layer was separated and back-extracted with dichloromethane. The combined organic extracts were washed with saturated sodium bicarbonate solution, then brine, then dried (MgSO<sub>4</sub>), and the solvent removed. The resulting residue was purified by silica gel  
 10 chromatography eluting with ethyl acetate/light petroleum (b.p. 40-60°C) to give the title product, m.p. 123-4°C.


[0082] The following compounds of formula In (see Table B), i.e. compounds of general formula I where Y is of formula (D) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl, R<sup>1</sup> and  
 15 R<sup>2</sup> are hydrogen and L is -NHC(=O)CH(R<sup>3</sup>)-, may be prepared by methods analogous to those of Example 2.



(In)

**Table B**

Cmp	R <sup>3</sup>	A <sup>2</sup>	m.p. (°C)
101	H	thienyl	oil
102	ethyl	phenyl	oil
103	MeC(=O)O-	phenyl	oil
104	H	2,4-diMeO-phenyl	oil
105	phenyl	phenyl	oil
106	Cl	phenyl	102-3

Cmp	R <sup>3</sup>	A <sup>2</sup>	m.p. (°C)
107	H	2,6-diCl-phenyl	136-9
108	H	2-NO <sub>2</sub> -phenyl	123-4
109	H	3-Cl-phenyl	88-9
110	H	2-Cl-6-F-phenyl	133-4
111	Pr <sup>i</sup>	1-imidazolyl	120
112	H		134

[0083] The <sup>1</sup>H N.M.R. data of those compounds in Table B which were not solid at room temperature are presented below.

5 Compound 101

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 3.9 (2H, s), 4.7 (2H, d), 7.0 (2H, d), 7.1 (1H, br.s), 7.3 (2H, m), 7.9 (1H, s) and 8.7 (1H, s);

Compound 102

10 <sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 0.9 (3H, t), 1.9 (1H, m), 2.25 (1H, m), 3.4 (1H, t), 4.7 (2H, qd), 6.9 (1H, bs), 7.2-7.4 (5H, m), 7.9 (1H, s), 8.65 (1H, s);

Compound 103

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 2.25 (3H, s), 4.75 (2H, d), 6.2 (1H, s), 7.4 (3H, m), 7.5 (2H, m), 7.7 (1H, bs), 8.0 (1H, s), 8.75 (1H, s);

Compound 104

15 <sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 3.65 (2H, s), 3.8 (3H, s), 3.9 (3H, s), 4.7 (2H, d), 6.8-7.0 (3H, m), 7.1 (1H, bs), 7.9 (1H, s), 8.75 (1H, s); and

Compound 105

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 4.8 (2H, d), 5.1 (1H, s), 7.1-7.4 (1H, m), 7.9 (1H, s) and 8.65 (1H, s).

**[0084] Example 3**

Methyl 2-[(2-chlorobenzyl)amino]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl]propanoate  
(Compound 218)

- 5 To a mixture of the product from stage h) below in tetrahydrofuran (12 ml) and methanol (4 ml) was added 1M sodium methoxide in methanol (4 drops) and the mixture was heated at 65°C for 3 days. The mixture was filtered and the solid washed successively with portions (5 ml) of methanol, dichloromethane and methanol. The combined filtrates were evaporated to give the title product. <sup>1</sup>H N.M.R δ (ppm) 8.63  
10 (1H, s), 7.89 (1H, s), 7.15-7.35 (4H, m), 3.92 (3H, m), 3.74 (3H, s), 3.42 (2H, d).

**[0085] Preparation of starting materials**

N-(tert-Butoxycarbonyl)glycine cesium salt

- To a mixture of N-(tert-butoxycarbonyl)glycine (42.0 g) in water (250 ml) was added  
15 cesium carbonate (39.1 g). The mixture was stirred at room temperature for 10 minutes. The water was removed by azeotropic distillation with toluene to give the title product.

**[0086] Attachment to Solid Support**

- 20 Merrifield resin (61.2 g) was swollen in dry dimethylformamide (350 ml). The product from stage a) (75.5 g) was added followed by more dry dimethylformamide (250 ml) and the mixture was stirred at 65°C overnight. On cooling, the mixture was filtered and the solid washed successively with portions (400 ml) of dimethylformamide, dimethylformamide/water (1:1), water, dichloromethane,  
25 methanol, dichloromethane and finally methanol (x2). The solid was dried in a vacuum oven overnight.

**[0087] Treatment with Trifluoroacetic Acid**

- To a mixture of the product from stage b) (76.2 g) swollen in dry dichloromethane  
30 (660 ml) was added trifluoroacetic acid (220 ml) and the mixture was stirred at room temperature for 5.5 hours. The mixture was filtered and the solid was washed

successively with portions (400 ml) of dichloromethane (x2), methanol, dichloromethane and methanol (x2). The resin was dried overnight.

**[0088] Treatment with Benzophenone Imine**

5 To a mixture of the product from stage c) (76.6 g) swollen in dry dichloromethane (650 ml) was added benzophenone imine (61 ml) in dichloromethane (100 ml) and the mixture stirred overnight. The mixture was filtered and the solid was successively washed with portions (400 ml) of dichloromethane, 20% aqueous tetrahydrofuran (x2), tetrahydrofuran, dichloromethane, methanol, dichloromethane and methanol  
10 (x2). The solid was dried in a vacuum oven overnight.

**[0089] Electrophilic Substitution of the Imine**

To a mixture of the product from stage d) (40.4 g) swollen in *N*-methylpyrrolidinone (250 ml) was added phosphazine base P(1)-*tert*-Bu-tris(tetramethylene) (38 ml). 3-  
15 Chloro-2-chloromethyl-5-trifluoromethylpyridine (42.4 g) was then added and the mixture was stirred at room temperature overnight. The mixture was filtered and the solid was washed successively with portions (200 ml) of *N*-methylpyrrolidinone (x2), dichloromethane (x2) methanol, dichloromethane and methanol (x2). The solid was dried in a vacuum oven overnight.

20

**[0090] Conversion of Imine to Amine Hydrochloride**

To a mixture of the product from stage e) (52.1 g) swollen in tetrahydrofuran (750 ml) was added 2M hydrochloric acid (250 ml). The mixture was stirred for 4 hours and then filtered. The solid was washed successively with portions (250 ml) of  
25 tetrahydrofuran (x2), dichloromethane (x2), methanol, dichloromethane, methanol and diethyl ether. The solid was dried in a vacuum oven overnight.

**[0091] Conversion to Amine**

A mixture of the product from stage f) in 10% triethylamine in dichloromethane was  
30 stirred at room temperature for 2 hours. The mixture was filtered and the solid was stirred in 5% triethylamine in dichloromethane for 1 hour. The mixture was filtered

again, and the solid was stirred in dichloromethane for 1 hour. The mixture was filtered and the solid washed successively with portions of methanol, dichloromethane, methanol and diethyl ether (x2). The solid was dried in a vacuum oven overnight.


5

**[0092] Conversion of Primary Amine to Secondary Amine**

A mixture of the product from stage g) (4.2 mmol) in trimethylorthoformate (90 ml) was treated with 2-chlorobenzaldehyde (42 mmol) and stirred at room temperature for 6 hours. Sodium cyanoborohydride (42 mmol) followed by acetic acid (1.3 ml) was then added and the mixture stirred at room temperature for 16 hours. The mixture was filtered and the solid was washed successively with portions of aqueous tetrahydrofuran, tetrahydrofuran, methanol, dichloromethane, methanol, dichloromethane, methanol and diethyl ether (x2). The solid was dried in a vacuum oven overnight.

15

**[0093]** The following compounds of formula Ip (see Table C), i.e. compounds of general formula I where Y is of formula (D) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl, R<sup>1</sup> and R<sup>2</sup> are hydrogen and L is -CH(R<sup>3</sup>)N(R<sup>5</sup>)CH<sub>2</sub>-, may be prepared by methods analogous to those of Example 3.



20

**Table C**

Cmp	R <sup>3</sup>	R <sup>5</sup>	A <sup>2</sup>	Characterising data
201	EtNHC(=O)-	H	phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.61 (1H, s), 7.8 (1H, s), 7.43 (1H, m), 7.1-7.3 (5H, m), 3.1-3.3 (7H, m), 1.16 (3H, t)

Cmp	R <sup>3</sup>	R <sup>5</sup>	A <sup>2</sup>	Characterising data
202	EtNHC(=O)-	MeC(=O)-	phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H, s), 7.73 (1H, s), 7.27 (3H, m), 7.10 (2H, m), 6.53 (1H, m), 5.82 (1H, t), 4.70 (2H, m), 3.43 (2H, m), 3.20 (2H, m), 2.14 (3H, s) and 1.03 (3H, t).
203	EtNHC(=O)-	H	3-tolyl	<sup>1</sup> H N.M.R δ (ppm) 8.63 (1H, s), 7.86 (1H, s), 7.54 (1H, m), 7.13 (1H, m), 7.06 (1H, m), 6.98 (2H, m), 3.1-3.8 (7H, m), 2.34 (3H, s), 1.17 (3H, t)
204	MeOC(=O)-	H	3-tolyl	<i>m/z</i> (ES) 387 (M+H) <sup>+</sup>
205	EtOC(=O)-	H	3-tolyl	<sup>1</sup> H N.M.R δ (ppm) 8.67 (1H, s), 7.88 (1H, s), 7.18 (1H, m), 7.02 (2H, m), 4.10 (2H, q), 3.78 (3H, m), 3.37 (2H, m), 2.32 (3H, s), 1.24 (3H, t)
206	EtNHC(=O)-	H	4-MeO-phenyl	<i>m/z</i> (ES) 416 (M+H) <sup>+</sup>
207	EtNHC(=O)-	H	2-Cl-phenyl	<i>m/z</i> (ES) 420 (M+H) <sup>+</sup>
208	EtNHC(=O)-	H	2,6-diF-phenyl	<i>m/z</i> (ES) 422 (M+H) <sup>+</sup>
209	EtNHC(=O)-	H	2-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 431 (M+H) <sup>+</sup>
210	EtNHC(=O)-	H	2-naphthyl	<i>m/z</i> (ES) 436 (M+H) <sup>+</sup>
211	EtNHC(=O)-	H	3,4-diMeO-phenyl	<i>m/z</i> (ES) 446 (M+H) <sup>+</sup>
212	EtNHC(=O)-	H	2-CF <sub>3</sub> -phenyl	<i>m/z</i> (ES) 454 (M+H) <sup>+</sup>
213	EtNHC(=O)-	H	2,4-diCl-phenyl	<i>m/z</i> (ES) 454 (M+H) <sup>+</sup>
214	EtNHC(=O)-	H	3-PhO-phenyl	<i>m/z</i> (ES) 478 (M+H) <sup>+</sup>
215	MeNHC(=O)-	H	2-Cl-phenyl	<i>m/z</i> (ES) 406 (M+H) <sup>+</sup>
216	MeNHC(=O)-	H	3-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 417 (M+H) <sup>+</sup>
217	MeOC(=O)-	H	4-MeO-phenyl	<i>m/z</i> (ES) 403 (M+H) <sup>+</sup>
218	MeOC(=O)-	H	2-Cl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.63 (1H, s), 7.89 (1H, s), 7.15-7.35 (4H, m), 3.92 (3H, m), 3.74 (3H, s), 3.42 (2H, d)

Cmp	R <sup>3</sup>	R <sup>5</sup>	A <sup>2</sup>	Characterising data
219	MeOC(=O)-	H	2,6-diF-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.83 (1H, s), 7.20 (1H, m), 6.34 (2H, m), 3.73 (3H, m), 3.68 (3H, s), 3.28 (2H, d)
220	MeOC(=O)-	H	2-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 418 (M+H) <sup>+</sup>
221	MeOC(=O)-	H	2-naphthyl	<i>m/z</i> (ES) 423 (M+H) <sup>+</sup>
222	MeOC(=O)-	H	3,4-diMeO-phenyl	<i>m/z</i> (ES) 433 (M+H) <sup>+</sup>
223	MeOC(=O)-	H	2-CF <sub>3</sub> -phenyl	<i>m/z</i> (ES) 441 (M+H) <sup>+</sup>
224	MeOC(=O)-	H	2,6-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.89 (1H, s), 7.1-7.35 (3H, m), 3.83 (3H, m), 3.72 (3H, s), 3.39 (2H, m)
225	MeOC(=O)-	H	3-PhO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.83 (1H, s), 6.3-7.2 (9H, m), 3.79 (3H, m), 3.71 (3H, s), 3.38 (2H, m)
226	EtOC(=O)-	H	phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.88 (1H, s), 7.1-7.3 (5H, m), 4.18 (2H, q), 3.79 (3H, m), 3.38 (2H, m), 1.21 (3H, t)
227	EtOC(=O)-	H	4-MeO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.63 (1H, s), 7.88 (1H, s), 7.12 (2H, d), 6.79 (2H, d), 4.10 (2H, q), 3.81 (3H, s), 3.73 (3H, m), 3.38 (2H, m), 1.23 (3H, t)
228	EtOC(=O)-	H	2-Cl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.86 (1H, s), 7.1-7.4 (4H, m), 4.19 (2H, q), 3.89 (3H, m), 3.40 (2H, m), 1.23 (3H, t)
229	EtOC(=O)-	H	2,6-diF-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.61 (1H, s), 7.82 (1H, s), 7.21 (1H, m), 6.82 (2H, t), 4.16 (2H, q), 3.91 (3H, m), 3.38 (2H, d), 1.22 (3H, t)
230	EtOC(=O)-	H	2-NO <sub>2</sub> -phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.87 (2H, m), 7.35-7.55 (3H, m), 4.20 (2H, m), 4.08 (2H, m), 3.36 (m), 3.37 (2H, m), 1.14 (3H, t)



Cmp	R <sup>3</sup>	R <sup>5</sup>	A <sup>2</sup>	Characterising data
231	EtOC(=O)-	H	2-naphthyl	<sup>1</sup> H N.M.R δ (ppm) 8.61 (1H, s), 7.25-7.9 (8H, m), 3.8-4.3 (5H, m), 3.41 (2H, m), 1.24 (3H, t)
232	EtOC(=O)-	H	3,4-diMeO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H, s), 7.89 (1H, s), 6.78 (3H, m), 4.19 (2H, q), 3.86 (3H, s), 3.81 (3H, s), 3.75 (2H, m), 3.39 (2H, m), 1.24 (3H, t)
233	EtOC(=O)-	H	2-CF <sub>3</sub> -phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.66 (1H, s), 7.91 (1H, s), 7.3-7.65 (4H, m), 4.21 (2H, m), 3.98 (3H, m), 3.41 (3H, m), 1.26 (3H, t)
234	EtOC(=O)-	H	2,4-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H, s), 7.89 (1H, s), 7.1-7.35 (3H, m), 4.20 (2H, m), 3.86 (3H, m), 3.40 (2H, m), 1.24 (3H, t)
235	EtOC(=O)-	H	3-PhO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.83 (1H, s), 6.8-7.4 (9H, m), 4.18 (2H, q), 3.77 (3H, m), 3.38 (2H, m), 1.22 (3H, t)
236	MeNHC(=O)-	H	2-naphthyl	<i>m/z</i> (ES) 422 (M+H) <sup>+</sup>
237	MeNHC(=O)-	H	2,4-diCl-phenyl	<i>m/z</i> (ES) 440 (M+H) <sup>+</sup>
238	MeNHC(=O)-	H	3-PhO-phenyl	<i>m/z</i> (ES) 464 (M+H) <sup>+</sup>
239	MeOC(=O)-	H	phenyl	<i>m/z</i> (ES) 373 (M+H) <sup>+</sup>


**[0094] Example 4****Methyl 2-bromobenzoylamino-3-(3-chloro-5-trifluoromethyl-2-pyridyl)propionate**  
**(Compound 321)**

- 5 To a mixture of the product from Example 3 stage g) in dry dichloromethane was added triethylamine and the solution was stirred for 15 minutes. 2-Bromobenzoyl chloride in dry dichloromethane was added, and the mixture was stirred at room temperature overnight. The mixture was filtered and the solid was washed successively with portions (125 ml) of dichloromethane (x2), methanol,
- 10 dichloromethane, methanol, dichloromethane (x2), methanol and diethyl ether (x2).

The solid was dried in a vacuum oven overnight. To this solid in tetrahydrofuran (12 ml) and methanol (4 ml) was added 1M sodium methoxide in methanol (4 drops) and the mixture was heated at 65°C for 3 days. The mixture was filtered and the solid washed successively with portions (5 ml) of methanol, dichloromethane and methanol. The combined filtrates were evaporated to give the title product.

<sup>1</sup>H N.M.R δ (ppm) 8.62 (s), 7.31 (s), 7.56 (2H, m), 7.37 (m), 7.29 (m), 5.40 (m), 3.76 (3H, s) and 3.71 (2H, m).

[0095] The following compounds of formula Iq (see Table D); i.e. compounds of general formula I where Y is of formula (D) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl, R<sup>1</sup> and R<sup>2</sup> are hydrogen and L is -CH(R<sup>3</sup>)NHC(=O)-, may be prepared by methods analogous to those of Example 4.



(Iq)

15

**Table D**

Cmp	R <sup>3</sup>	A <sup>2</sup>	Characterising data
301	EtNHC(=O)-	4-MeO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.66 (1H, s), 7.91 (1H, s), 7.89 (1H, d), 7.77 (2H, d), 6.94 (2H, d), 6.32 (1H, d), 6.32 (1H, d), 5.21 (1H, m), 3.97 (3H, s), 3.55 (2H, m), 3.25 (2H, m), 1.08 (3H, t)
302	EtNHC(=O)-	2,6-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.60 (1H, s), 7.91 (1H, s), 7.2-7.4 (3H, m), 6.74 (1H, m), 5.33 (1H, m), 3.62 (2H, m), 3.29 (2H, m), 1.12 (3H, t)
303	EtNHC(=O)-	cyclopropyl	<i>m/z</i> (ES) 364 (M+H) <sup>-</sup>
304	EtNHC(=O)-	phenyl	<i>m/z</i> (ES) 400 (M+H) <sup>-</sup>
305	EtNHC(=O)-	cyclohexyl	<i>m/z</i> (ES) 406 (M+H) <sup>-</sup>

Cmp	R <sup>3</sup>	A <sup>2</sup>	Characterising data
306	EtNHC(=O)-	4-Cl-phenyl	<i>m/z</i> (ES) 435 (M+H) <sup>+</sup>
307	EtNHC(=O)-	3-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 445 (M+H) <sup>+</sup>
308	EtNHC(=O)-	3-CF <sub>3</sub> -phenyl	<i>m/z</i> (ES) 468 (M+H) <sup>+</sup>
309	EtNHC(=O)-	4-PhO-phenyl	<i>m/z</i> (ES) 476 (M+H) <sup>+</sup>
310	EtNHC(=O)-	2-Br-phenyl	<i>m/z</i> (ES) 478 (M+H) <sup>+</sup>
311	MeNHC(=O)-	cyclopropyl	<sup>1</sup> H N.M.R δ (ppm) 8.67 (1H, s), 7.92 (1H, s), 6.70 (1H, br), 5.09 (1H, m), 3.46 (2H, m), 2.80 (3H, m), 1.42 (1H, m), 0.97 (2H, m), 0.81 (2H, m)
312	MeNHC(=O)-	cyclohexyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H, s), 7.91 (1H, s), 7.08 (1H, d), 6.68 (1H, m), 5.04 (1H, q), 3.43 (2H, m), 2.73 (3H, m), 1.2-2.3 (11H, m)
313	MeNHC(=O)-	2,6-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.85 (1H, s), 7.46 (1H, d), 7.34 (3H, m), 4.82 (1H, m), 5.36 (1H, m), 3.62 (2H, m), 2.84 (3H, d)
314	MeNHC(=O)-	phenyl	<i>m/z</i> (ES) 386 (M+H) <sup>+</sup>
315	MeNHC(=O)-	4-MeO-phenyl	<i>m/z</i> (ES) 416 (M+H) <sup>+</sup>
316	MeNHC(=O)-	4-biphenyl	<i>m/z</i> (ES) 462 (M+H) <sup>+</sup>
317	MeOC(=O)-	phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.95 (1H, s), 7.93 (2H, m), 7.26 (3H, m), 5.38 (1H, m), 3.76 (3H, s), 3.70 (2H, m)
318	MeOC(=O)-	cyclohexyl	<sup>1</sup> H N.M.R δ (ppm) 8.66 (1H, s), 7.91 (1H, s), 6.63 (1H, d), 5.18 (1H, m), 3.71 (3H, s), 3.57 (2H, m), 1.2-2.15 (11H, m)
319	MeOC(=O)-	2,6-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.60 (1H, s), 7.95 (1H, s), 7.28 (3H, m), 1.03 (1H, d), 5.42 (2H, m), 3.74 (5H, m)
320	MeOC(=O)-	4-biphenyl	<sup>1</sup> H N.M.R δ (ppm) 8.72 (1H, s), 7.92 (1H, s), 7.35-7.9 (9H, m), 5.39 (1H, m), 3.78 (3H, s), 3.70 (2H, m)
321	MeOC(=O)-	2-Br-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H, s), 7.31 (1H, s), 7.56 (2H, m), 7.37 (1H, m), 7.29 (1H, m), 5.40 (1H, m), 3.76 (3H, s), 3.71 (2H, m)

Cmp	R <sup>3</sup>	A <sup>2</sup>	Characterising data
322	EtOC(=O)-	cyclohexyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H. s), 7.92 (1H. s), 6.64 (1H. d), 5.16 (1H. m), 4.18 (2H. m), 3.59 (2H. m), 0.3-2.2 (11H. m), 1.22 (3H. t)
323	EtOC(=O)-	4-MeO-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.69 (1H. s), 7.91 (1H. s), 7.77 (2H. d), 7.38 (1H. d), 8.92 (2H. d), 5.32 (1H. m), 4.20 (2H. m), 3.34 (3H. t), 3.67 (2H. m)
324	EtOC(=O)-	3-CF <sub>3</sub> -phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.68 (1H. s), 8.06 (1H. s), 7.96 (2H. m), 7.30 (2H. m), 7.60 (2H. m), 5.36 (1H. m), 4.21 (2H. m), 3.71 (2H. m), 1.23 (3H. t)
325	EtOC(=O)-	2,6-diCl-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.62 (1H. s), 7.94 (1H. s), 7.26 (3H. m), 7.04 (1H. d), 5.41 (1H. m), 4.21 (2H. m), 3.73 (2H. m), 1.22 (3H. t)
326	EtOC(=O)-	2-Br-phenyl	<sup>1</sup> H N.M.R δ (ppm) 8.64 (1H. s), 7.93 (1H. s), 7.57 (1H. m), 7.33 (1H. m), 7.26 (1H. m), 5.39 (1H. m), 4.22 (2H. m), 3.75 (2H. m), 1.23 (3H. t)
327	MeOC(=O)-	cyclopropyl	<i>m/z</i> (ES) 351 (M+H) <sup>+</sup>
328	MeOC(=O)-	4-MeO-phenyl	<i>m/z</i> (ES) 417 (M+H) <sup>+</sup>
329	MeOC(=O)-	4-Cl-phenyl	<i>m/z</i> (ES) 421 (M+H) <sup>+</sup>
330	MeOC(=O)-	3-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 432 (M+H) <sup>+</sup>
331	MeOC(=O)-	3-CF <sub>3</sub> -phenyl	<i>m/z</i> (ES) 455 (M+H) <sup>+</sup>
332	EtOC(=O)-	cyclopropyl	<i>m/z</i> (ES) 365 (M+H) <sup>+</sup>
333	EtOC(=O)-	phenyl	<i>m/z</i> (ES) 401 (M+H) <sup>+</sup>
334	EtOC(=O)-	4-Cl-phenyl	<i>m/z</i> (ES) 435 (M+H) <sup>+</sup>
335	EtOC(=O)-	3-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 446 (M+H) <sup>+</sup>
336	EtOC(=O)-	4-biphenyl	<i>m/z</i> (ES) 477 (M+H) <sup>+</sup>
337	MeNHC(=O)-	4-Cl-phenyl	<i>m/z</i> (ES) 420 (M+H) <sup>+</sup>
338	MeNHC(=O)-	3-NO <sub>2</sub> -phenyl	<i>m/z</i> (ES) 431 (M+H) <sup>+</sup>
339	MeNHC(=O)-	3-CF <sub>3</sub> -phenyl	<i>m/z</i> (ES) 454 (M+H) <sup>+</sup>
340	MeNHC(=O)-	2-Br-phenyl	<i>m/z</i> (ES) 464 (M+H) <sup>+</sup>

[0096] Example 5N-[2-(3-Chloro-5-trifluoromethyl-2-pyridyl)ethyl]-2,6-dichlorobenzamide(Compound 401)

To a suspension of 2-(3-chloro-5-trifluoromethyl-2-pyridyl)ethylammonium chloride (0.2 g) in dry dichloromethane at 10°C was added 2,6-dichlorobenzoyl chloride (0.13 ml) followed by dropwise addition of dry triethylamine (0.3 ml). The mixture was warmed with stirring to 22°C over 18 hours. The mixture was evaporated on to flash silica. Chromatography over silica eluting with 20-50% diethyl ether in light petroleum (b.p. 40-60°C) gave the title product. m.p. 103-5°C.

10

[0097] Preparation of Starting Material2-(3-Chloro-5-trifluoromethyl-2-pyridyl)ethylammonium chloride

To a solution of the product from Example 6 (1.0 g) in ethanol (10 ml) was added hydrazine hydrate (0.15 ml) and the mixture was heated under reflux for 3 hours.

Concentrated hydrochloric acid (1 ml) was added and the mixture was heated at 80°C for 1 hour to give a filterable precipitate. The mixture was cooled to 10°C, filtered and then evaporated to dryness *in vacuo*. The residue was dissolved in water (10 ml) and then basified to greater than pH 10 using 2M aqueous sodium hydroxide solution. The aqueous solution was ether extracted (3x15 ml) and the combined extracts were brine washed (2x10 ml). The organic extract was dried (MgSO<sub>4</sub>), the filtrate acidified with 6M hydrogen chloride in diethyl ether (5 ml) and evaporated to dryness. The solid residue was triturated with ethyl ether, filtered and dried *in vacuo* to give the title compound. m.p. 188-92°C.

25 [0098] Example 62-{2-[3-Chloro-5-(trifluoromethyl)-2-pyridyl]ethyl}-1,3-isoindolinedione(Compound 402)

To a solution of the product from Example 7 (5.63 g) in glacial acetic acid (50 ml) was added 48% hydrogen bromide solution (10 ml) and the mixture was heated at 120°C for 2 hours. The cold mixture was evaporated *in vacuo* and partitioned between water (100 ml) and dichloromethane (100 ml). The aqueous layer was

30

separated and extracted with dichloromethane (2x10 ml). The combined extracts were water washed (2x20 ml), dried (MgSO<sub>4</sub>), and evaporated onto flash silica. Chromatography over silica eluting with 3-30% diethyl ether in light petroleum (b.p. 40-60°C) gave the title compound, m.p. 147-8°C.

5

**[0099] Example 7**

Diethyl 2-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-2-[(1,3-dioxo-2,3-dihydro-1H-2-isoindolyl)methyl]malonate

(Compound 403)

10 To a suspension of 60% sodium hydride (0.65 g) in dry dimethylformamide (20 ml) at 0°C was added a solution of diethyl 2-(3-chloro-5-trifluoromethyl-2-pyridyl)malonate (5 g) in dry dimethylformamide (10 ml) and the mixture was stirred for 15 minutes. A solution of *N*-bromomethylphthalimide (3.55 g) in dry dimethylformamide (10 ml) was added dropwise and the mixture was warmed with stirring to 22°C over 18 hours. Glacial acetic acid (1 ml) was added and the mixture was poured into cold water (500 ml). The aqueous solution was extracted with diethyl ether (3x150 ml) and the combined extract was water washed (3x100 ml). The organic extract was dried (MgSO<sub>4</sub>) and evaporated to give a crude product. 15 Trituration with diethyl ether/light petroleum (b.p. 40-60°C) (1:1) gave the title compound, m.p. 159-61°C. 20

**[0100] Preparation of Starting Materials**

Diethyl 2-(3-chloro-5-trifluoromethyl-2-pyridyl)malonate

To a suspension of 60% sodium hydride in mineral oil (5.28 g) in dry dimethylformamide (50 ml) at 0°C was added a solution of diethyl malonate (10 ml) in dry dimethylformamide (25 ml) and the mixture was stirred for 30 minutes. A solution of 2,3-dichloro-5-(trifluoromethyl)pyridine (9.8 ml) in dry dimethylformamide (10 ml) was added dropwise and the mixture warmed with stirring to 22°C over 18 hours. Acetic acid (7.5 ml) in diethyl ether (20 ml) was added dropwise and the mixture was stirred until hydrogen evolution had ceased. The mixture was diluted with diethyl ether (600 ml) and then water washed (3x200 ml). 25 30

The organic extract was dried ( $\text{MgSO}_4$ ) and evaporated onto flash silica.

Chromatography over silica eluting with 0-20% diethyl ether in light petroleum (b.p.

40-60°C) gave the title compound.  $^1\text{H}$  N.M.R. ( $\text{CDCl}_3$ )  $\delta$ (ppm) 1.28 (6H, t, 2x

$\text{CH}_3\text{CH}_2$ ), 4.30 (4H, q, 2x $\text{CH}_2\text{CH}_3$ ), 5.24 (1H, s,  $\text{CH}(\text{CO}_2\text{Et})_2$ ), 7.96 (1H, s, py-H),

5 8.74 (1H, s, py-H).

### [0101] Example 8

#### (Compound 501)

To a solution of *O*-{[3-chloro-5-(trifluoromethyl)-2-pyridyl]methyl} hydroxylamine  
10 (0.4 g) and triethylamine (0.18 g) in tetrahydrofuran (20 ml) was added 2,6-dichlorobenzoyl chloride (0.37 g). The reaction mixture was stirred for 20 hours at room temperature before filtering the solution and evaporation of the filtrate. The resulting residue was redissolved in ethyl acetate and washed successively with dilute hydrochloric acid, saturated sodium bicarbonate solution and water. The organic  
15 phase was dried, filtered and evaporated to yield the crude product which was further purified by silica gel column chromatography to give the title compound.

### [0102] Preparation of Starting Material


#### *O*-{[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl} hydroxylamine

To a solution of *N*-hydroxyphthalimide (3.55 g) in dimethylformamide (50 ml) was  
20 added potassium carbonate (3.0 g) to give a thick yellow suspension which was stirred for 1 hour. 3-Chloro-2-chloromethyl-5-trifluoromethylpyridine (5.0 g) was added and the reaction stirred at room temperature for 20 hours. The mixture was filtered and the filtrate poured into water. The resulting white solid was isolated by  
25 filtration, washed with water, redissolved in ethyl acetate and the organic solution dried and evaporated to yield the intermediate phthalimide as a white solid. The phthalimide (2.0 g) was dissolved in methanol (20 ml) and the resulting solution treated with hydrazine hydrate (0.42 g). The reaction was left to stand for 19 hours before heating at reflux for 3 hours to yield a white precipitate. The reaction mixture  
30 was filtered and the methanol filtrate evaporated. The residue was treated with

diethyl ether and refiltered. Evaporation of the filtrate yielded the title compound as a green yellow oil.


[0103] The following compounds of general formula I where Y is of formula (D) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl. R<sup>1</sup> and R<sup>2</sup> are hydrogen and L is -O-NHC(=O)-, may be prepared by methods analogous to those of Example 8:

Compound 501 m.p. 127-9°C



and

Compound 502 m.p. 108-10°C



[0104] Example 9

N-[(3-Chloro-5-trifluoromethyl-2-pyridyl)methyl]-3-(2-tolyl)propionamide

(Compound 602)

To a mixture of (3-chloro-5-trifluoromethyl-2-pyridyl)methylamine hydrochloride (1 mmol, 0.247 g) in tetrahydrofuran (5 ml) was added triethylamine (2 mmol, 0.202 g) at room temperature and the mixture was stirred at room temperature for 1 hour. The mixture was filtered and the filtrate added to a solution of 3-(2-tolyl)propionyl chloride (1.1 mmol, 0.2 g) in tetrahydrofuran (5 ml) at room temperature. After 4 hours stirring at room temperature the solvent was evaporated and the residue washed with water. The solid was filtered and washed with diethyl ether/light petroleum (1:20) to give the title product, m.p. 152-3°C.



**[0105] Example 10****N-Benzyl-N'-(3-chloro-5-trifluoromethyl-2-pyridyl)methylthiourea****(Compound 604)**

- 5 To a mixture of (3-chloro-5-trifluoromethyl-2-pyridyl)methylamine hydrochloride (0.12 g) and benzylisothiocyanate (0.11 g) in dry tetrahydrofuran (10 ml) was added triethylamine (10 drops) and the mixture stirred at room temperature for 12 hours. The solvent was evaporated and ethyl acetate added. The mixture was washed with 2M hydrochloric acid and then with saturated sodium bicarbonate solution. The
- 10 organic layer was separated and the solvent removed to give the title product. <sup>1</sup>H N.M.R. δ(ppm) 4.7 (2H, broad s), 4.95 (2H, d), 6.9 (1H, broad s), 7.3-7.55 (6H, m), 7.95 (1H, s) and 8.58 (1H, s).

**[0106] Example 11****N-[(3-Chloro-5-trifluoromethyl-2-pyridyl)methyl]-2-phenylthiopropionamide****(Compound 615)**

- A mixture of thiophenol (55 mg) and potassium *tert*-butoxide (56 mg) in tetrahydrofuran (5 ml) was stirred at room temperature for 30 minutes. Starting material (see below) (173 mg) was added and the mixture was heated at 65°C with
- 20 stirring for 2 hours. When cool, the mixture was evaporated and the residue was purified by silica gel chromatography to give the title product. <sup>1</sup>H N.M.R. δ(ppm) 1.6 (3H, d), 3.9 (1H, q), 4.67 (2H, d), 7.25 (3H, m), 7.38 (2H, m), 7.9 (1H, s), 8.0 (1H, broad s) and 8.7 (1H, s).

**[0107] Preparation of starting material****N-[(3-Chloro-5-trifluoromethyl-2-pyridyl)methyl]-2-bromopropionamide**

- To a mixture of (3-chloro-5-trifluoromethyl-2-pyridyl)methylamine hydrochloride (1.0 g) in tetrahydrofuran (5 ml) and triethylamine (0.41 g) which had been stirred at room temperature for 30 minutes, was added a mixture of 2-bromopropionic acid
- 30 (0.62 g) and carbonyldiimidazole (0.65 g) in tetrahydrofuran (5 ml) which had also been stirred at room temperature for 30 minutes. The combined mixture was stirred

at room temperature for 12 hours and then the solvent was removed. The residue was partitioned between diethyl ether and water and the layers separated. The organic phase was dried (MgSO<sub>4</sub>) and the solvent removed to give the title product.

5 [0108] Example 12

3-(3-Chloro-5-trifluoromethyl-2-pyridyl)methylamino)-1-phenylbut-2-enone  
(Compound 610)

To a suspension of (3-chloro-5-trifluoromethyl-2-pyridyl)methylamine hydrochloride (2.5 g) in dry tetrahydrofuran (20 ml) was added anhydrous sodium acetate (1.64 g) and benzoyl acetone (1.62g). The suspension was stirred at 20°C for 18 hours, then  
10 heated at 50°C for 4 hours. The mixture was evaporated and the residue partitioned between ethyl acetate and water. The organic extracts were dried (MgSO<sub>4</sub>), filtered and evaporated to give a solid. The solid was triturated with diethyl ether, filtered and washed with diethyl ether to give the title product. m.p. 123-5°C.

15

[0109] Example 13

3-(3-Chloro-5-trifluoromethyl-2-pyridyl)methylamino)-1-(2,6-dichlorophenyl)-propenone  
(Compound 612)

20 The title compound was prepared in analogous fashion to Example 4 replacing benzoyl acetone with 1-(2,6-dichlorophenyl)-3-hydroxypropenone (see below). Purification was performed by silica gel chromatography eluting with 2% triethylamine in diethyl ether/light petroleum (b.p. 40-60°C) (1:1) to give a mixture of E and Z isomers. <sup>1</sup>H N.M.R. δ(ppm) 4.54 (2H. m. py-CH<sub>2</sub>), 4.76 (2H. m. py-CH<sub>2</sub>), 5.24 (1H. m. HNCH=CH), 5.60 (1H. m. HNCH=CH), 6.72 (1H. broad s. NH),  
25 CH<sub>2</sub>), 7.02-7.35 (8H. m. 2xHNCH=CH-, 6xAr-H), 7.42 (1H. broad s. NH), 7.96 (2H. d. 2xpy-H), 8.7 (1H. s. py-H), 8.86 (1H. s. py-H) and 10.5 (4H. broad s. 2xN<sup>+</sup>H<sub>2</sub>Cl).

**[0110] Preparation of starting materials**

**1-(2,6-Dichlorophenyl)-3-dimethylaminopropenone**

To a solution of 2,6-dichloroacetophenone (2 g) in dry dimethylformamide dimethyl acetal (10 ml) was added pyridinium 4-toluene sulfonate (0.2 g). The mixture was stirred under nitrogen and heated to reflux for 90 minutes. An azeotrope of dimethylformamide dimethylacetal/methanol was distilled under nitrogen to complete loss of 2,6-dichloroacetophenone by thin layer chromatography. The cold mixture was evaporated to give a solid. The solid was triturated with 10% diethyl ether in light petroleum (b.p. 40-60°C), filtered and washed with the same to give the title compound. m.p. 98-100°C.

**[0111] 1-(2,6-Dichlorophenyl)-3-hydroxypropenone**

To a solution of the product from stage a) (1.2 g) in acetone (20 ml) and water (2 ml) was added dry Amberlyst 15 resin (2 g) and the mixture was refluxed with stirring under nitrogen for 18 hours. The solution was vacuum filtered and the filtrate evaporated. The residue was dissolved in diethyl ether (50 ml) and dried (MgSO<sub>4</sub>). The filtrate was presorbed onto silica gel (10 g) and purified by silica gel chromatography gradient eluting with 20 to 30% diethyl ether in light petroleum (b.p. 40-60°C) to give the title compound.

**[0112] Example 14**

**(9-Fluorenylmethyl) N-[(3-Chloro-5-trifluoromethyl-2-pyridyl)methyl]carbamate**  
**(Compound 601)**


A mixture of the starting material (see below) (1.97 g), dioxane (40 ml), water (20 ml) and concentrated hydrochloric acid (10 ml) was refluxed for 48 hours. On cooling, diethyl ether (100 ml) was added and the layers separated. The organic layer was washed with water (50 ml), dried (MgSO<sub>4</sub>) and the solvent removed to give a solid which was recrystallised from toluene. m.p. 159-61°C.

**[0113] Preparation of starting material**

(9-Fluorenylmethyl) N-[(3-chloro-5-trifluoromethyl-2-pyridyl)- $\alpha$ -ethoxycarbonylmethyl]carbamate

- 5 To a mixture of 3-chloro-5-trifluoromethyl-2-pyridyl- $\alpha$ -ethoxycarbonylmethyl ammonium chloride (1.91 g) in dichloromethane (25 ml) and triethylamine (0.85 ml), was added N-(9-fluorenylmethoxycarbonyloxy)succinimide (2.02 g) and the mixture was stirred at room temperature for 90 minutes. Water (15 ml) was then added and the layers separated. The aqueous phase was extracted with dichloromethane and the  
10 combined organic layers were dried (MgSO<sub>4</sub>) and the solvent removed. The residue was purified by silica gel chromatography gradient eluting with diethyl ether/light petroleum (b.p. 40-60°C) to give the title compound.

- [0114]** The following compounds of formula Ir (see Table E), i.e. compounds of  
15 general formula I where Y is of formula (E) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl and R<sup>1</sup> is hydrogen, may be prepared by methods analogous to the above Examples.




(Ir)

**Table E**

Cmp	L <sup>1</sup>	R <sup>2</sup>	A <sup>3</sup>	m.p. (°C)
601	-NH-C(=O)O-CH <sub>2</sub> -	H	9-fluorenyl	159-61
602	-NH-C(=O)-(CH <sub>2</sub> ) <sub>2</sub> -	H	2-tolyl	152-3
603	-NH-C(=O)NH-CH <sub>2</sub> -	H	phenyl	oil
604	-NH-C(=S)NH-CH <sub>2</sub> -	H	phenyl	oil
605	-NH-C(=O)NH-CH <sub>2</sub> -	H	3-Cl-5-CF <sub>3</sub> -2-pyridyl	153-4
606	-N(Et)-C(=O)CH <sub>2</sub> O-	CO <sub>2</sub> Et	phenyl	96-9

Cmp	L <sup>1</sup>	R <sup>2</sup>	A <sup>3</sup>	m.p. (°C)
607	-NH-C(=O)CH <sub>2</sub> O-	H	phenyl	123
608	-NH-C(=O)CH <sub>2</sub> S-	H	phenyl	102-3
609	-NHC(=O)CH=CH-	H	phenyl	110-1
610	-NHC(Me)=CH-C(=O)-	H	phenyl	123-5
611	-NHC(=O)CH=CH-	H	2,6-diCl-phenyl	168-9
612	-NHCH=CH-C(=O)-	H	2,6-diCl-phenyl	129
613	-NH-C(=O)-C(Me) <sub>2</sub> O-	H	4-Cl-phenyl	65
614	-NH-C(=O)-CH(Me)O-	H	2,6-diCl-phenyl	131
615	-NH-C(=O)-CH(Me)S-	H	phenyl	oil
616	-NH-C(=O)CH <sub>2</sub> O-	H	2,4-diCl-phenyl	149
617	-NH-C(=O)CH <sub>2</sub> O-	H	4-Cl-phenyl	116
618	-NH-C(=O)CH <sub>2</sub> S-	H	3-(4-tolyl)-1,2,4-thiadiazol-5-yl	162
619	-NH-C(=O)CH <sub>2</sub> O-	H	4-tolyl	116
620	-NH-C(=O)CH <sub>2</sub> O-	H	4-Cl-benzthiazol-2-yl	106
621	-NH-C(=O)CH <sub>2</sub> O-	H	2-biphenyl	93
622	-NH-C(=O)CH <sub>2</sub> O-	H	3,5-diCl-2-tolyl	100
623	-NH-C(=O)CH <sub>2</sub> O-	H	2-Cl-phenyl	82
624	-NH-C(=O)CH <sub>2</sub> S-	H	4,6-diCl-3-tolyl	118
625	-NH-C(=O)CH <sub>2</sub> S-	H	4-tolyl	109
626	-NH-C(=O)CH(Me)O-	H	4-Cl-phenyl	oil
627	-NH-C(=O)CH(Me)O-	H	phenyl	88
628	-NH-C(=O)CH(Me)O-	H	6-Cl-3-tolyl	oil
629	-NH-C(=O)CH(Ph)O-	H	5-Cl-2-tolyl	150
630	-NH-C(=O)CH(-CH <sub>2</sub> OMe)O-	H	2,4,5-triCl-phenyl	152
631	-NH-C(=O)CH(Me)O-	H	2-tolyl	150
632	-NH-C(=O)CH(-CH <sub>2</sub> OMe)O-	H	2,4-diCl-phenyl	80

Cmp	L <sup>1</sup>	R <sup>2</sup>	A <sup>3</sup>	m.p. (°C)
633	-NH-C(=O)CH(Et)O-	H	4-Cl-2-OH-phenyl	83
634	-NH-C(=O)CH(Ph)O-	H	2,4,5-triCl-phenyl	138
635	-NH-C(=O)CH(Me)S-	H	7-CF <sub>3</sub> -quinolin-4-yl	131
636	-NH-C(=O)CH(Me)S-	H	benzthiazol-2-yl	108
637	-NH-C(=O)CH(Me)S-	H	3-(2-Cl-phenyl)-1,2,4-thiadiazol-5-yl	oil
638	-NH-C(=O)CH(Me)S-	H	2-Me-1-Ph-1,2,4-triazol-3-yl	oil
639	-NH-C(=O)CH(Me)S-	H	3-Me-1,2,4-thiadiazol-5-yl	oil
640	-NH-C(=O)CH(Me)S-	H	1-cyclohexyltetrazol-5-yl	oil
641	-NH-C(=O)CH(Me)S-	H		oil
642	-NH-C(=O)CH(Me)S-	H	5-CF <sub>3</sub> -benzthiazol-2-yl	120
643	-NH-C(=O)CH(Me)S-	H	5-Cl-benzthiazol-2-yl	132
644	-NH-C(=O)CH(Me)S-	H	2-pyridyl	oil
645	-NH-C(=O)CH(Me)S-	H	1-Me-tetrazol-5-yl	98
646	-NH-C(=O)CH(Me)S-	H	4,6-diMe-pyrimidin-2-yl	132
647	-NH-C(=O)CH(Me)S-	H	benzoxazol-2-yl	72
648	-NH-C(=O)CH(Me)S-	H	2-MeO-phenyl	100
649	-NH-C(=O)CH(Me)S-	H	1-Me-imidazol-2-yl	oil
650	-NH-C(=O)CH(Me)S-	H	1-Me-1,3,4-triazol-2-yl	98
651	-NH-C(=O)CH(Me)S-	H	5-CF <sub>3</sub> -2-pyridyl	98
652	-NH-C(=O)CH(Me)S-	H	5-Me-1,3,4-thiadiazol-2-yl	oil
653	-NH-C(=O)CH(Me)S-	H	2-(CO <sub>2</sub> Me)-phenyl	118
654	-NH-C(=O)CH(Me)S-	H	3-Cl-5-CF <sub>3</sub> -2-pyridyl	104
655	-NH-C(=O)CH(Me)S-	H	2-Cl-phenyl	73
656	-NH-C(=O)CH(Me)S-	H	2,6-diCl-phenyl	75
657	-NH-C(=O)CH(Me)O-	H	4-Br-3,5-diMe-phenyl	121

Compound 603

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 4.4 (2H, s), 4.7 (2H, s), 7.2-7.4 (5H, m), 7.9 (1H, s) and 8.65 (1H, s);

5 Compound 626

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.55 (3H, d), 4.75 (3H, m), 6.8 (2H, d), 7.2 (2H, d), 7.7 (1H, br.s), 7.85 (1H, s) and 8.6 (1H, s);

Compound 628

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.55 (3H, d), 2.3 (3H, s), 4.75 (3H, m), 6.65 (1H, m), 6.8 (1H, s), 7.2 (1H, m), 7.7 (1H, br.s), 7.85 (1H, s) and 8.6 (1H, s);

Compound 637

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.65 (3H, d), 4.6 (2H, d), 4.65 (1H, q), 7.25-7.45 (3H, m), 7.75 (1H, s), 7.8 (1H, s), 7.9 (1H, d) and 8.3 (1H, br.s);

Compound 638

15 <sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.55 (3H, d), 2.4 (3H, s), 4.3 (1H, q), 4.7 (2H, q), 7.3-7.5 (5H, m), 7.8 (1H, s), 8.15 (1H, s) and 8.4 (1H, br.s);

Compound 639

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.6 (3H, d), 2.6 (3H, s), 4.6 (1H, q), 4.65 (2H, s), 7.85 (1H, s), 8.1 (1H, br.s) and 8.65 (1H);

20 Compound 640

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.15-2.0 (13H, m), 4.0-4.1 (1H, m), 4.6 (2H, s), 7.8 (1H, s), 8.0 (1H, br.s) and 8.6 (1H, s);

Compound 641

25 <sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.25 (3H, s), 1.35 (3H, s), 1.5 (3H, d), 4.45 (1H, q), 4.75 (2H, qd), 5.05 (2H, d), 7.85 (1H, s), 8.15 (1H, br.s) and 8.6 (1H, s);

Compound 644

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.6 (3H, d), 4.5-4.75 (3H, m), 7.0 (1H, t), 7.1 (1H, m), 7.4 (1H, m), 7.8 (1H, s), 8.4 (1H, d), 8.55 (1H, s) and 8.7 (1H, br.s);


Compound 649

<sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.5 (3H, d), 3.5 (3H, s), 4.15 (1H, q), 4.6 (2H, qd), 6.8 (1H, s), 7.0 (1H, s), 7.8 (1H, s), 8.65 (1H, s) and 8.75 (1H, br.s); and

Compound 652

- 5 <sup>1</sup>H N.M.R. (CDCl<sub>3</sub>) δ(ppm) 1.6 (3H, d), 2.65 (3H, s), 4.65 (3H, m), 7.8 (1H, m), 8.15 (1H, br.s) and 8.6 (1H, s).

[0115] The following compounds of formula Is (see Table F), i.e. compounds of general formula I where Y is a formula (E) and A<sup>1</sup> is 3-Cl-5-CF<sub>3</sub>-2-pyridyl, R<sup>1</sup> is  
 10 hydrogen and L<sup>1</sup> is -NHC(=O)CH(R<sup>8</sup>)N(R<sup>9</sup>)-, may be prepared by methods analogous to the above Examples.




(Is)

Table F

Cmp	R <sup>2</sup>	R <sup>8</sup>	R <sup>9</sup>	A <sup>3</sup>	m.p. (°C)
701	H	H	H	2-Me-benzoyl	126
702	H	Me (racemic)	H	benzyloxycarbonyl	114
703	H	Pr <sup>i</sup>	H	isopropylloxycarbonyl	134
704	H	Bu <sup>i</sup>	H	isopropylloxycarbonyl	142
705	H	Bu <sup>i</sup>	Me	isopropylloxycarbonyl	oil
706	Me	Pr <sup>i</sup>	H	isopropylloxycarbonyl	151
707	Me	Bu <sup>i</sup>	H	isopropylloxycarbonyl	134
708	Me	Bu <sup>i</sup>	Me	isopropylloxycarbonyl	oil




Compound 801 m.p. 148°C



and

Compound 802 m.p. 185°C



5

#### [0116] Test Example

Compounds were assessed for activity against one or more of the following:

- 10 *Phytophthora infestans*: late tomato blight
- Plasmopara viticola*: vine downy mildew
- Erysiphe graminis f. sp. tritici*: wheat powdery mildew
- Pyricularia oryzae*: rice blast
- Leptosphaeria nodorum*: glume blotch

15

[0117] Aqueous solutions or dispersions of the compounds at the desired concentration, including a wetting agent, were applied by spray or by drenching the stem base of the test plants, as appropriate. After a given time, plants or plant parts were inoculated with appropriate test pathogens before or after application of the compounds as appropriate, and kept under controlled environmental conditions suitable for maintaining plant growth and development of the disease. After an appropriate time, the degree of infection of the affected part of the plant was visually estimated. Compounds are assessed on a score of 1 to 3 where 1 is little or no control, 2 is moderate control and 3 is good to total control. At a concentration of 500


20

ppm (w/v) or less, the following compounds scored 2 or more against the fungi specified.

5	<u><i>Phytophthora infestans</i></u> :	31 and 105-7.
	<u><i>Plasmopara viticola</i></u> :	50, 55, 104, 105, 201, 215, 221, 222, 224, 225, 227, 230, 232, 233, 234, 235, 328 and 606.
10	<u><i>Erysiphe graminis f. sp. tritici</i></u> :	4, 25, 26, 39, 40, 44, 101, 201, 214, 304, 305, 306, 308, 310, 312, 313, 603, 606 and 642.
	<u><i>Pyricularia oryzae</i></u> :	111, 112, 306, 312, 606, 624, 645, 650 and 701.
15	<u><i>Leptosphaeria nodorum</i></u> :	13, 105, 107, 108, 201, 229, 232, 238, 317, 336 and 626.

CLAIMS

- 5 1. The use of a compound of general formula I. complexes and salts thereof as phytopathogenic fungicides



(I)


where

- $A^1$  is 2-pyridyl or its *N*-oxide, each of which may be substituted by up to four groups  
 10 at least one of which is haloalkyl;

Y is a formula (D) or (E):



(D)



(E)

$A^2$  is heterocyclyl or carbocyclyl, each of which may be substituted:

- 15  $A^3$  is heterocyclyl or carbocyclyl, each of which may be substituted, or acyl:

L is a 3-atom linker, selected from the list:  $-N(R^5)C(=X)N(R^6)-$ ,

$-N(R^5)C(=X)CH(R^3)-$ ,  $-CH(R^3)N(R^5)CH(R^4)-$ ,  $-CH(R^3)N(R^5)C(=X)-$ ,

$-N(R^3)CH(R^4)C(=X)-$  and  $-O-N(R^5)C(=X)-$ ; wherein  $A^1$  is attached to the left hand side of linker L:

- 20  $L^1$  is a 4-atom linker selected from the list:  $-N(R^9)C(=X)-X^1-CH(R^7)-$ ,

$-N(R^9)C(=X)CH(R^7)CH(R^8)-$ ,  $-N(R^9)C(=X)C(R^7)=C(R^8)-$ ,

$-N(R^9)C(R^7)=C(R^8)-C(=X)-$ ,  $-N(R^9)C(R^7)=C(R^8)-SO_2-$ ,

$-N(R^9)C(=X)C(R^7)(R^8)-SO_2-$  and  $-N(R^9)C(=X)C(R^7)(R^8)-X^1-$ ; wherein  $A^1$  is attached to the left hand side of linker  $L^1$ ;

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^7$  and  $R^8$ , which may be the same or different, are  $R^b$ , cyano, nitro, halogen,  $-OR^b$ ,  $-SR^b$  or optionally substituted amino;

$R^5$  and  $R^6$  which may be the same or different, are  $R^b$ , cyano or nitro;

or any  $R^1$ ,  $R^3$  or  $R^5$  group, together with the interconnecting atoms, can form a 3-,

5 4-, 5- or 6-membered ring with any  $R^2$ ,  $R^4$  or  $R^6$  or any  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  or  $R^6$  group, together with the interconnecting atoms can form a 5- or 6-membered ring with  $A^2$ ;

or  $R^1$  and  $R^2$ , or  $R^7$  and  $R^8$ , together with the interconnecting atoms, may form a 3-, 4-, 5- or 6-membered ring, which may be substituted:

10  $R^b$  is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen or acyl;

X is oxygen or sulfur;

$X^1$  is oxygen, sulfur or  $-N(R^9)-$ ; and

$R^9$  is  $R^b$ , cyano or nitro, or  $R^9$  and  $A^3$ ,  $R^1$ ,  $R^2$ ,  $R^7$  or  $R^8$ , together with the  
15 interconnecting atoms, may form a 3-, 4-, 5- or 6-membered ring, which may be substituted.

2. A method of combating fungal pests at a locus infested or liable to be infested therewith, which comprises applying to the locus a compound as defined in claim 1,  
20 or a complex or salt thereof.

3. A method of combating phytopathogenic fungi at a locus infested or liable to be infested therewith, which comprises applying to the locus a compound as defined in claim 1, or a complex or salt thereof.

25

4. A method according to claim 2 or 3 in which the said compound is applied at an application rate of from 5 to 1000 g per hectare.

5. A pesticidal composition comprising at least one compound as defined in claim 1, or a complex or salt thereof, in admixture with an agriculturally acceptable diluent or carrier.
- 5 6. A fungicidal composition comprising at least one compound as defined in claim 1, or a complex or salt thereof, in admixture with an agriculturally acceptable diluent or carrier.
7. A compound of formula I as defined in claim 1 or a complex or salt thereof in  
10 which one or more of the following features are present:
- a)  $A^2$  is optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted cyclohexyl or optionally substituted cyclopropyl; or
- b)  $A^3$  is optionally substituted phenyl, optionally substituted heterocyclyl or acyl; or
- 15 c)  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^7$  and  $R^8$  are hydrogen, optionally substituted alkyl, optionally substituted phenyl, cyano, acyl or halogen (more preferably  $R^1$  and  $R^2$  are hydrogen); or
- d)  $R^5$  and  $R^6$  are hydrogen, optionally substituted alkyl or acyl; or
- e)  $R^7$  and  $R^8$  are hydrogen, optionally substituted alkyl or acyl; or
- 20 f)  $R^9$  is hydrogen or optionally substituted alkyl; or
- g) the 2-pyridyl group ( $A^1$ ) is substituted by alkoxy, alkyl, cyano, halogen, nitro, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl or trifluoromethyl, (preferably chlorine or trifluoromethyl).
- 25 8. A compound of formula I as defined in claim 1 or a complex or salt thereof in which:
- Y is -L- $A^2$ - and:
- i) L is -NHC(=X)NH-; and

A<sup>2</sup> is phenyl optionally substituted by halogen, haloalkyl, phenoxy, alkoxy, alkyl, CN, NO<sub>2</sub>, SO<sub>2</sub>-(N-tetrahydropyridinyl), alkylthio, acyl, phenylsulphonyl, dialkylamino, alkylsulphonyl, benzylsulphonyl, S(phenyl substituted by halogen); or A<sup>2</sup> is cycloalkyl; or naphthyl optionally substituted by NO<sub>2</sub>; or

5 ii) L is -NHC(=O)CH(R<sup>3</sup>)-;

R<sup>3</sup> is hydrogen, alkyl, phenyl, halogen or acyloxy;

A<sup>2</sup> is phenyl optionally substituted by halogen, NO<sub>2</sub> or alkoxy; or thienyl; or imidazolyl; or pyrrolinyl substituted by alkoxy; or

iii) L is -CH(R<sup>3</sup>)N(R<sup>5</sup>)CH<sub>2</sub>-;

10 R<sup>3</sup> is N-alkylcarbamoyl or alkoxycarbonyl;

R<sup>5</sup> is hydrogen or acyl;

A<sup>2</sup> is phenyl optionally substituted by alkyl, alkoxy, halogen, NO<sub>2</sub>, haloalkyl or phenoxy; or is naphthyl; or

iv) L is -CH(R<sup>3</sup>)NHC(=O)-;

15 R<sup>3</sup> is N-alkylcarbamoyl or alkoxycarbonyl;

A<sup>2</sup> is phenyl optionally substituted by alkoxy, halogen, NO<sub>2</sub>, haloalkyl, phenoxy or phenyl; or is cycloalkyl; or

v) L is -O-NHC(=O)- and A<sup>2</sup> is phenyl substituted by alkyl;  
or

20 Y is -L<sup>1</sup>-A<sup>3</sup>- and:

a) L<sup>1</sup> is -NHC(=O)(CH<sub>2</sub>)<sub>2</sub>-, and A<sup>3</sup> is phenyl substituted by alkyl; or

b) L<sup>1</sup> is -NHC(=S)NHCH<sub>2</sub>-, and A<sup>3</sup> is phenyl; or

c) L<sup>1</sup> is -NHC(=O)CH(alkyl)S-, and A<sup>3</sup> is phenyl; or

d) L<sup>1</sup> is -NHC(=O)OCH<sub>2</sub>-, -NHC(=O)(CH<sub>2</sub>)<sub>2</sub>-, -NHC(=O)NHCH<sub>2</sub>-,

25 -NHC(=S)NHCH<sub>2</sub>-, -N(alkyl)C(=O)CH<sub>2</sub>O- or -NHC(=O)CH<sub>2</sub>O-;

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is hydrogen or alkoxycarbonyl;

A<sup>3</sup> is phenyl optionally substituted by halogen, alkyl, phenyl, OH, alkoxy or alkoxy carbonyl; or fluorenyl; or pyridyl optionally substituted by halogen or haloalkyl; or thiadiazolyl substituted by alkyl; or benzthiazolyl optionally substituted by halogen or by phenyl substituted by halogen; or quinolinyl substituted by haloalkyl; or triazolyl substituted by alkyl or phenyl; or tetrazolyl substituted by alkyl or cycloalkyl; or pyrimidinyl substituted by alkyl; or benzoxazolyl; or imidazolyl substituted by alkyl; or thiazolinyl substituted by alkyl and methylene; or

e) L<sup>1</sup> is -NHC(=O)CH(R<sup>8</sup>)N(R<sup>9</sup>)-;

R<sup>1</sup> is hydrogen;

10 R<sup>2</sup> is hydrogen or alkyl;

R<sup>8</sup> and R<sup>9</sup> are each hydrogen or alkyl;

A<sup>3</sup> is benzoyl optionally substituted by alkyl; or benzyloxycarbonyl; or alkoxy carbonyl; or

f) L<sup>1</sup> is -NHC(=O)CH(alkyl)SO<sub>2</sub>-;

15 R<sup>1</sup> and R<sup>2</sup> are each hydrogen;

A<sup>3</sup> is phenyl; or

g) L<sup>1</sup> is -NHC(=O)CH<sub>2</sub>X<sup>1</sup>-; where X<sup>1</sup> and A<sup>3</sup> form a 2-oxo-N-benzthiazolyl ring which is substituted by halogen; and

R<sup>1</sup> and R<sup>2</sup> are each hydrogen.

# INTERNATIONAL SEARCH REPORT

Inter Application No  
PCT/EP 00/08143

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A01N43/40 A01N47/12 A01N47/32 C07D213/61 C07D409/12  
C07D413/12 C07D417/12 C07D213/65

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 17840 A (AGREVO UK LTD ;DOELLER UWE (DE); BRAUN PETER (DE); SACHSE BURKHARD) 13 June 1996 (1996-06-13) claims	1-8
A,P	WO 99 42447 A (MOLONEY BRIAN ANTHONY ;SAVILLE STONES ELIZABETH ANNE (GB); AGREVO) 26 August 1999 (1999-08-26) cited in the application claims	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

21 December 2000

Date of mailing of the international search report

02/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Decorte, D



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9617840 A	13-06-1996	AU 4265596 A	26-06-1996
WO 9942447 A	26-08-1999	AU 2527199 A	06-09-1999
		EP 1056723 A	06-12-2000
		NO 20004159 A	17-10-2000

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

RECU D.P.I.

17 JUL 2001

PCT

To:

TETAZ, Franck  
Aventis CropScience S.A.  
14-20, rue Pierre Baizet  
B.P. 9163  
F-69263 Lyon Cedex 09  
FRANCE

*Handwritten initials: U, J, J, J, P, and a signature.*

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing  
(day/month/year) 12.07.2001

Applicant's or agent's file reference  
99C111 G1

### IMPORTANT NOTIFICATION

International application No.  
PCT/EP00/08143

International filing date (day/month/year)  
09/08/2000

Priority date (day/month/year)  
18/08/1999

Applicant  
AVENTIS CROPSCIENCE GMBH et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Gallego, A

Tel. +49 89 2399-8102



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>99C111 G1</b>	<div style="text-align: center;"><b>FOR FURTHER ACTION</b></div> <div style="text-align: right; font-size: small;">See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)</div>	
International application No. <b>PCT/EP00/08143</b>	International filing date ( <i>day/month/year</i> ) <b>09/08/2000</b>	Priority date ( <i>day/month/year</i> ) <b>18/08/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>A01N43/40</b>		
Applicant <b>AVENTIS CROPS SCIENCE GMBH et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
  
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
 

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of    sheets.

3. This report contains indications relating to the following items:
 

I	<input checked="" type="checkbox"/> Basis of the report
II	<input type="checkbox"/> Priority
III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/> Lack of unity of invention
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input checked="" type="checkbox"/> Certain documents cited
VII	<input type="checkbox"/> Certain defects in the international application
VIII	<input checked="" type="checkbox"/> Certain observations on the international application

Date of submission of the demand  <b>21/02/2001</b>	Date of completion of this report  <b>12.07.2001</b>
Name and mailing address of the international preliminary examining authority:  <div style="display: flex; align-items: center;"> <div>             European Patent Office              D-80298 Munich              Tel. +49 89 2399 - 0 Tx: 523656 epmu d              Fax: +49 89 2399 - 4465           </div> </div>	Authorized officer  <b>Bertrand, F</b>  Telephone No. +49 89 2399 8606



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/08143.

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-48 as originally filed

**Claims, No.:**

1-8 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
  - ☐ the language of publication of the international application (under Rule 48.3(b)).
  - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
  - ☐ filed together with the international application in computer readable form.
  - ☐ furnished subsequently to this Authority in written form.
  - ☐ furnished subsequently to this Authority in computer readable form.
  - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
  - ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4. The amendments have resulted in the cancellation of:
- ☐ the description, pages:
  - ☐ the claims, Nos.:
  - ☐ the drawings, sheets:
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/08143

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1-8
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-8
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1,3-8
	No:	Claims	2?

2. Citations and explanations  
**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re Item I**

**Basis of the report**

The documents mentioned in this International Preliminary Examination Report are numbered in accordance with the order they appear in the International Search Report.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Claim 2 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT). The scope is **not** limited to crop-protection uses and encompasses methods to control fungi on human and animal bodies (locus). The other claims are regarded as susceptible of industrial application.

The priority documents pertaining to the present application were not available at the time of establishing this written opinion. Hence, it is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the document indicated in the international search report as P (see Item VI, certain documents cited) could become relevant to assess whether the present claims satisfy the criteria set forth in Article 33(1) PCT.

The present application relates to the use of compounds of formula (I) as fungicides and to a subgroup thereof *per se*.

D1 relates to fungicidal compounds having a different general formula, which is not overlapping the present one and does not show a high structural similarity.

Therefore, the present application meets the requirements of Articles 33(2)&(3) PCT, insofar as the claimed subject-matter is new with respect to the prior art as defined in Rule 64(1) to (3) PCT and involves an inventive step (Rule 65(1) and (2) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/08143

**Re Item VI**

**Certain documents cited**

**Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 99/42447	26.08.1999	16.02.1999	19.02.1998
			30.06.1998
			11.08.1998

**Re Item VIII**

**Certain observations on the international application**

The formula (I) obviously contains an error: Y should be read instead of L-A<sup>2</sup>.

# INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT/EP 00/08143

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A01N43/40 A01N47/12 A01N47/32 C07D213/61 C07D409/12  
C07D413/12 C07D417/12 C07D213/65

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 17840 A (AGREVO UK LTD ;DOELLER UWE (DE); BRAUN PETER (DE); SACHSE BURKHARD) 13 June 1996 (1996-06-13) claims	1-8
A,P	WO 99 42447 A (MOLONEY BRIAN ANTHONY ;SAVILLE STONES ELIZABETH ANNE (GB); AGREVO) 26 August 1999 (1999-08-26) cited in the application claims	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

21 December 2000

Date of mailing of the international search report

02/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Decorte, D



# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/08143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9617840 A	13-06-1996	AU 4265596 A	26-06-1996
WO 9942447 A	26-08-1999	AU 2527199 A	06-09-1999
		EP 1056723 A	06-12-2000
		NO 20004159 A	17-10-2000

**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**

**(PCT Article 36 and Rule 70)**

Applicant's or agent's file reference <b>99C111 G1</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/EP00/08143</b>	International filing date (day/month/year) <b>09/08/2000</b>	Priority date (day/month/year) <b>18/08/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>A01N43/40</b>		
Applicant <b>AVENTIS CROPSCIENCE GMBH et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>21/02/2001</b>	Date of completion of this report  <b>12.07.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> <b>Tel. +49 89 2399 - 0 Tx: 523656 epmu d</b> <b>Fax: +49 89 2399 - 4465</b>	Authorized officer  <b>Bertrand, F</b>  Telephone No. <b>+49 89 2399 8606</b>



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/08143

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-48 as originally filed

**Claims, No.:**

1-8 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/08143

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

## **V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

### **1. Statement**

Novelty (N)	Yes:	Claims	1-8
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-8
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1,3-8
	No:	Claims	2?

2. Citations and explanations  
**see separate sheet**

## **VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

## **VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/08143

**Re Item I**

**Basis of the report**

The documents mentioned in this International Preliminary Examination Report are numbered in accordance with the order they appear in the International Search Report.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Claim 2 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT). The scope is **not** limited to crop-protection uses and encompasses methods to control fungi on human and animal bodies (locus). The other claims are regarded as susceptible of industrial application.

The priority documents pertaining to the present application were not available at the time of establishing this written opinion. Hence, it is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the document indicated in the international search report as P (see Item VI, certain documents cited) could become relevant to assess whether the present claims satisfy the criteria set forth in Article 33(1) PCT.

The present application relates to the use of compounds of formula (I) as fungicides and to a subgroup thereof *per se*.

D1 relates to fungicidal compounds having a different general formula, which is not overlapping the present one and does not show a high structural similarity.

Therefore, the present application meets the requirements of Articles 33(2)&(3) PCT, insofar as the claimed subject-matter is new with respect to the prior art as defined in Rule 64(1) to (3) PCT and involves an inventive step (Rule 65(1) and (2) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/08143

**Re Item VI**

**Certain documents cited**

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 99/42447	26.08.1999	16.02.1999	19.02.1998
			30.06.1998
			11.08.1998

**Re Item VIII**

**Certain observations on the international application**

The formula (I) obviously contains an error: Y should be read instead of  $L-A^2$ .

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>99C111G1</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 00/ 08143</b>	International filing date (day/month/year) <b>09/08/2000</b>	(Earliest) Priority Date (day/month/year) <b>18/08/1999</b>
Applicant  <b>AVENTIS CROPSCIENCE GMBH</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.


☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

## Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)



The invention relates to compounds of general formula I:



where

$A^1$  is 2-pyridyl or its *N*-oxide, each of which may be substituted by up to four groups at least one of which is haloalkyl;

Y is a formula (D) or (E):



$A^2$  is heterocyclyl or carbocyclyl, each of which may be substituted;

$A^3$  is heterocyclyl or carbocyclyl, each of which may be substituted, or acyl;

L is a 3-atom linker and  $L^1$  is a 4-atom linker as defined in the description;

$R^1$  and  $R^2$  the same or different, are  $R^b$ , cyano, nitro, halogen,  $-OR^b$ ,  $-SR^b$  or optionally substituted amino;

or  $R^1$  and  $R^2$  may form a 3-,

4-, 5- or 6-membered ring, which may be substituted;

$R^b$  is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen or acyl; and to their use as phytopathogenic fungicides.